Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 1 of 137 Protocol #: BMX-HGG-001  A Phase 1/2 Study  A Phase 1/2 Trial for Patients with Newly Diagnosed High Grade Glioma Treated with Concurrent Radiation Therapy, Temozolomide, and  BMX-001     Sponsor: BioMimetix JV, LLC  Funding Source: BioMimetix JV, LLC WIRB (Central IRB) Study #: 20151095 IND# 124640   Medical Monitor: Elizabeth A. Regan, MD, PhD BioMimetix JV, LLC [PHONE_12270] (cell) [EMAIL_11274]    Coordinating Center for Biostatistics and Imaging Duke University  Coordinating Principal Investigator  [INVESTIGATOR_34480], MD, PhD, FAAN The Preston Robert Tisch Brain Tumor Center Duke University Medical Center Box 3624 Durham, NC [ZIP_CODE]            
May 28, 2021

Protocol #: BMX-HGG-[ADDRESS_780121] read and understand the BMX-HGG-001 protocol named above and agree to carry out all of its terms in accordance with applicable regulations and laws. I assure that the study drug supplied by [CONTACT_591723].    Principal Investigator [INVESTIGATOR_591693] #: BMX-HGG-[ADDRESS_780122] OF ABBREVIATIONS ............................................................................................................................... 9	5	PROTOCOL SYNOPSIS ..................................................................................................................................11	5.1	Purpose ............................................................................................................................................11	5.2	Phase 1 ............................................................................................................................................11	5.2.1	Primary Objective ........................................................................................................................11	5.2.2	Secondary Objectives ...................................................................................................................11	5.2.3	Exploratory Objectives .................................................................................................................11	5.3	Phase 2 ............................................................................................................................................11	5.3.1	Primary Objective ........................................................................................................................11	5.3.2	Secondary Objectives ...................................................................................................................11	5.3.3	Exploratory Objectives .................................................................................................................12	5.4	Design and Procedure.......................................................................................................................12	5.4.1	Phase 1 (Enrollment Complete) ....................................................................................................12	5.4.2	Phase 2 ........................................................................................................................................13	5.5	Selection of Subjects.........................................................................................................................13	5.5.1	Inclusion Criteria ..........................................................................................................................13	5.5.2	Exclusion Criteria .........................................................................................................................14	5.5.3	BMX-001 Specific Concerns ..........................................................................................................14	5.6	Risk/Benefit Assessment ...................................................................................................................15	5.6.1	Potential Benefits ........................................................................................................................15	5.6.2	Risks of BMX-001 .........................................................................................................................15	5.6.3	Risks of TMZ ................................................................................................................................16	5.6.4	Radiation Treatment Side Effects .................................................................................................17	5.6.5	Risks of Phlebotomy .....................................................................................................................17	5.6.6	Risks of MRI .................................................................................................................................17	5.6.7	Unknown Risks.............................................................................................................................18	5.7	Data Analysis and Statistical Considerations ......................................................................................18	6	STUDY SCHEMA ...........................................................................................................................................19	7	BACKGROUND AND SIGNIFICANCE ..............................................................................................................20	7.1	Study Disease ...................................................................................................................................20	7.2	Radiation-Induced Damage during Brain Tumor Treatment ...............................................................20	7.3	Cognition and HRQoL in HGG ............................................................................................................20	7.4	Thrombocytopenia ...........................................................................................................................22	
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 5 of 137 7.5	BMX-001 ..........................................................................................................................................24	7.6	Study Rationale ................................................................................................................................25	8	OBJECTIVES AND ENDPOINTS ......................................................................................................................26	9	INVESTIGATIONAL PLAN ..............................................................................................................................29	9.1	Study Design ....................................................................................................................................29	9.1.1	Phase 1 Specific Design ................................................................................................................29	9.1.2	Phase 2 Specific Design ................................................................................................................31	9.1.3	Safety Considerations ..................................................................................................................31	9.1.4	Prolongation of QTc Interval and Management ............................................................................32	9.1.5	Missed Doses ...............................................................................................................................32	9.1.6	Concomitant Medications ............................................................................................................33	9.1.7	TMZ Treatment Plan ....................................................................................................................33	9.1.8	Radiation Treatment Plan.............................................................................................................33	9.1.9	Randomization .............................................................................................................................34	9.2	Rationale for Selection of Dose and Regimen ....................................................................................35	9.3	Rationale for Correlative Studies.......................................................................................................35	9.4	Definition of Evaluable Subjects ........................................................................................................35	9.5	Data collection for subjects unable to come to clinical center ...........................................................35	9.6	Early Study Termination....................................................................................................................35	10	STUDY DRUG (BMX-001) ..............................................................................................................................[ADDRESS_780123] Formulation and Manufacture ................................................................................36	10.2.2	Labels for BMX-001 for Injection, 10 mg/mL .................................................................................37	10.2.3	Syringe and Label for Administration of BMX-001 for Injection, 10 mg/mL ....................................37	10.2.4	Multi-Dose Kits ............................................................................................................................37	10.3	Supply, Receipt, and Storage ............................................................................................................38	10.4	Compliance and Accountability .........................................................................................................38	10.5	Disposal and Destruction ..................................................................................................................38	11	STUDY DRUG (TMZ) .....................................................................................................................................[ADDRESS_780124] ELIGIBILITY ....................................................................................................................................39	
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 6 of 137 13	SCREENING AND ON-STUDY TESTS AND PROCEDURES .................................................................................40	13.1	Screening Examination .....................................................................................................................41	13.2	Run-In Period ...................................................................................................................................42	13.3	Chemoradiation Treatment Period (with and without BMX-001) .......................................................[ADDRESS_780125](s) ..................................................................................................................43	13.7.1	Criteria for Early Withdrawal ........................................................................................................43	13.7.2	Follow-up Requirements for Early Withdrawal .............................................................................44	13.8	Study Assessments ...........................................................................................................................44	13.8.1	Medical History ............................................................................................................................44	13.8.2	Physical and Neurological Examinations .......................................................................................44	13.8.3	Electrocardiogram (ECG) ..............................................................................................................44	13.8.4	Radiographic Response ................................................................................................................45	13.8.5	HRQoL .........................................................................................................................................46	13.8.6	Cognitive Testing .........................................................................................................................47	13.8.7	Hair Integrity and Hair Loss ..........................................................................................................49	13.8.8	Medical and Demographic Information ........................................................................................49	13.8.9	Bone Marrow Assessments ..........................................................................................................49	13.8.10	MRI Diffusion Tensor/Susceptibility Imaging.................................................................................[ADDRESS_780126] (DSMB) ..........................................................................52	15	QUALITY CONTROL AND QUALITY ASSURANCE ............................................................................................54	15.1	Monitoring .......................................................................................................................................54	15.1.1	DSMB-Plus ...................................................................................................................................54	15.2	Audits...............................................................................................................................................55	15.3	Data Management and Processing ....................................................................................................55	15.3.1	Study Documentation ..................................................................................................................55	
Protocol #: BMX-HGG-[ADDRESS_780127] ............................................................................................................................67	18	REFERENCES ................................................................................................................................................68	19	APPENDICES ................................................................................................................................................72	19.1	Appendix A: RANO (Radiographic Assessment in Neuro-Oncology) Criteria for Newly Diagnosed Patients 72	19.2	Appendix B: Pharmacokinetic Analysis ..............................................................................................76	19.2.1	Phase 1 Pharmacokinetic Analysis ................................................................................................76	19.2.2	Phase 2 Pharmacokinetic Analysis ................................................................................................77	19.3	APPENDIX C: Statistical Tables ..........................................................................................................[ADDRESS_780128] STAGE WITH COHORTS OF 3 .........86	
Protocol #: BMX-HGG-[ADDRESS_780129] STAGE WITH COHORTS OF 3 .........90	19.4	Appendix D Cytochrome P450 Drug Interaction Table .......................................................................93	19.5	Appendix E Copy of BAC App screenshots .........................................................................................94	 94	19.6	Appendix F:  Beck Depression Inventory- II (BDI-II) .......................................................................... 103	19.7	Appendix G:  FACIT-Fatigue............................................................................................................. 109	19.8	Appendix H:  Fact-BR ...................................................................................................................... 110	19.9	Appendix I:  FACT-Cog..................................................................................................................... 115	19.10	Appendix J:  Godin Leisure-Time Exercise Questionnaire ................................................................. 118	19.11	Appendix K:  Trails Making Test (TMT) Parts A & B .......................................................................... 120	19.12	Appendix L:  HVLT-R Forms 1, 2 and 3 ............................................................................................. 125	19.1	Appendix M:  COWA ....................................................................................................................... 137	   
Protocol #: BMX-HGG-[ADDRESS_780130]-Br Functional Assessment of Cancer Therapy-Brain FDA  Food and Drug Administration GBM Glioblastoma Gy  Gray HIF-1 Hypoxia-inducible factor-1 HGG High Grade Glioma H&P History & Physical Exam HRPP Human Research Protections Program HRQoL Health-Related Quality of Life ICS  Investigational Clinical Site IRB  Institutional Review Board KPS   Karnofsky Performance Scale MDS Myelodysplastic Syndrome MnSOD Manganese Superoxide Dismutase MOS Median Overall Survival MRI  Magnetic Resonance Imaging MTD Maximum Tolerated Dose NCI  National Cancer Institute NFĸB  Nuclear Factor Kappa B ORR  Overall Response Rate OS  Overall Survival PD  Progressive Disease PFS  Progression-free Survival PFS-6 Progression-free Survival at 6 months p.o.  per os/by [CONTACT_1966]/orally PR  Partial Response PRO  Patient-Reported Outcome PRT-BTC Preston Robert Tisch Brain Tumor Center QTc  Corrected QT Interval RIO  Research Integrity Office RT  Radiation Therapy SAE  Serious Adverse Event SD  Stable Disease SGOT Serum Glutamic Oxaloacetic Transaminase 
Protocol #: BMX-HGG-[ADDRESS_780131]   
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 11 of 137 5 PROTOCOL SYNOPSIS  5.1 Purpose This is a Phase 1/[ADDRESS_780132] radiation therapy (RT) and temozolomide (TMZ) in the treatment of newly diagnosed high grade glioma (HGG) patients. Phase 1 was conducted as a single site study at the Preston Robert Tisch Brain Tumor Center at Duke (PRT-BTC). Phase 2 will be conducted as a multi-center study and will include up to 10 additional sites besides the PRT-BTC at Duke. 5.2 Phase 1  5.2.1 Primary Objective 1. To determine the maximum tolerated dose (MTD) of BMX-[ADDRESS_780133] RT and TMZ in newly diagnosed HGG patients based upon overall survival (OS) and progression free survival (PFS). 3. To examine the impact on cognition of BMX-[ADDRESS_780134] RT and TMZ. 5. To characterize the pharmacokinetic profile of BMX-001 when delivered in combination with RT and TMZ in newly diagnosed HGG patients. 5.2.3 Exploratory Objectives 1. To describe patient-reported outcomes of health-related quality of life (HRQoL) in newly diagnosed HGG patients treated with BMX-[ADDRESS_780135] on overall survival (OS) of standard RT and TMZ in combination with BMX-[ADDRESS_780136] on progression-free survival (PFS) of standard RT and TMZ in combination with BMX-[ADDRESS_780137] RT and TMZ alone in newly diagnosed HGG patients.  
Protocol #: BMX-HGG-[ADDRESS_780138] RT and TMZ alone. 5.4 Design and Procedure 5.4.1 Phase 1 (Enrollment Complete) In the Phase [ADDRESS_780139] dosing of daily TMZ and RT in patients with newly diagnosed HGG (WHO grade III or IV). The dose escalation will be guided by a CRM design to determine the MTD of BMX-[ADDRESS_780140] as a loading dose given 0 to 4 days before the start of chemoradiation and then at a subsequent dose (50% of the loading dose) twice a week for eight weeks. There will only be two doses per week regardless of whether the dose is a loading or maintenance dose. TMZ will be dosed at 75 mg/m2 orally daily for [ADDRESS_780141] 3 subjects at the initial dose level of 0.1 mg/kg dose level, the rules provided in Section [IP_ADDRESS] will be used to determine dose assignments for subsequent subjects and whether dose can be escalated. If a subject terminates protocol treatment without experiencing a DLT and before completing standard chemoradiation, then the subject will not be evaluable for the determination of DLT and will be replaced.  It is estimated that a maximum of 18 subjects will be required for Phase 1. The maximum tolerated dose (MTD), defined as the dose that has an estimated DLT rate nearest to 0.25, will be the dose used in the future Phase [ADDRESS_780142] dose of BMX-001 will be administered subcutaneously in the morning as a loading dose. Blood will be drawn on the following days: loading dose day, Day 8 or the next date on which drug is administered, and Day 36 or the next date on which drug is administered. Measures will be obtained at the following times: Predose, 0.5 hour, 1 hour, 2 hours, 6 hours, and 24 hours. Samples will be analyzed for BMX-001 using validated analytical methods at a laboratory identified by [CONTACT_456]. See Appendix B for details (Section 19.2).  With accrual in Phase I complete, a total of 17 subjects were enrolled. Enrollment numbers for Phase 1 broken down by [CONTACT_591724]:  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 13 of 137 Dosing Group Loading Dose Maintenance Dose Number of Subjects Treated 1 7 mg/subject 3.5 mg/subject b.i.w. 4 2 14 mg/subject 7 mg/subject b.i.w. 3 3 28 mg/subject 14 mg/subject b.i.w. 6 4 42 mg/subject 20 mg/subject b.i.w. [ADDRESS_780143] of concurrent daily TMZ and RT with BMX-001 (Arm A) versus concurrent daily TMZ and RT alone (Arm B) on survival in patients with newly diagnosed HGG (WHO grade III and IV). The loading dose for Arm A determined from the Phase 1 component of this protocol is 28 mg/subject with a 14 mg/subject maintenance dose given twice weekly. Subjects will be randomized with a treatment arm allocation ratio of 1:1 and there will be 160 patients enrolled in this phase of the study (80 subjects per arm). Subjects in Arm A will be administered BMX-[ADDRESS_780144] as a loading dose given 0 to 4 days before the start of chemoradiation and then at subsequent dose twice a week for eight weeks. Subjects in Arm A and Arm B will receive TMZ dosed at 75 mg/m2 orally daily for [ADDRESS_780145] of care (SOC) clinic visits (approximately 8 weeks apart +/- 2 weeks) until death, or patient’s choice to discontinue study measures.  Cognitive testing should continue after noted progression until the 12 month follow up timepoint is reached (testing may be done at a visit following the 12 month timepoint).    In order to characterize the repeated dose pharmacokinetic profiles of BMX-001 in combination with RT and TMZ in newly diagnosed HGG patients, pharmacokinetic blood samples will be drawn from six patients in the Phase 2 portion of the study on Days 8 and 36 only (see Section 19.2.2). The first 6 patients enrolled and assigned to Arm A at PRT-BTC at Duke will participate in the PK portion. Measures will be obtained at approximately the following times: Pre-dose, then 0.[ADDRESS_780146]-dose. Samples will be analyzed for BMX-001 using validated analytical methods at a laboratory identified by [CONTACT_456]. See Appendix B for details (Section 19.2). 5.5 Selection of Subjects The inclusion/exclusion criteria for the Phase [ADDRESS_780147] of care radiation therapy and chemotherapy (temozolomide) 3. Subjects must be within [ADDRESS_780148] major neurosurgical procedure for the high-grade glioma (craniotomy, open biopsy, or stereotactic biopsy) 4. Subjects must have had a definitive resection with residual radiographic contrast enhancement on post-resection CT or MRI of less than or equal to 3 cm in any two perpendicular planes on any images   5. Age ³ 18 years 6. Karnofsky Performance Status (KPS) ≥ 70% 7. Hemoglobin ≥ 9.0 g/dl, ANC ≥ 1,500 cells/µl, platelets ≥ 125,000 cells/µl 8. Serum creatinine ≤ 1.5 mg/dl, serum SGOT and bilirubin ≤ 1.[ADDRESS_780149]  
Protocol #: BMX-HGG-[ADDRESS_780150] agree to use appropriate contraceptive measures for the duration of the study and for 12 months afterwards as stated in the informed consent 11. If using corticosteroids:  stable and/or decreasing dose of corticosteroids for greater than or equal to [ADDRESS_780151] be fluent in English (due to the neurocognitive testing and the Brief Assessment of Cognition (BAC) application only being available in English)  5.5.[ADDRESS_780152]-feeding 2. Active infection requiring IV antibiotics within 7 days before enrollment 3. Signs of wound-healing problems or infection at the craniotomy/biopsy site 4. Prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin 5. Co-medication that may interfere with study results; e.g. immuno-suppressive agents other than corticosteroids 6. Prior treatment with radiotherapy for a brain tumor, irrespective of the grade of the tumor 7. Prior allergy to temozolomide 8. Prior progression on adjuvant temozolomide dosed at 150 mg/m2 to 200 mg/m2 on Days 1-5 of a 28-day cycle 9. Evidence of > grade [ADDRESS_780153] scan  10. Systemic treatment with inducers or strong inhibitors of cytochrome P450 within four days before enrollment or planned treatment during the study drug treatment period of the study (see Appendix D).  11. Metal in the body that is not compatible with MRI 12. Severe allergy to contrast agents 5.5.3 BMX-001 Specific Concerns Subjects meeting any of the following criteria are ineligible for study entry:  1. Inadequately controlled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure > 100 mmHg) within [ADDRESS_780154] study treatment 2. Active or history of postural hypotension and autonomic dysfunction 3. Clinically significant (i.e. active) cardiovascular disease or cerebrovascular disease, for example cerebrovascular accidents ≤ 6 months prior to study enrollment, myocardial infarction ≤ 6 months prior to study enrollment, unstable angina, [LOCATION_001] Heart Association (NYHA) Grade II or greater congestive heart failure (CHF), or serious cardiac arrhythmia uncontrolled by [CONTACT_167739]  4. History or evidence upon physical/neurological examination of central nervous system disease (e.g. seizures) unrelated to cancer unless adequately controlled by [CONTACT_167739] 5. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months prior to start of study treatment 6. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >480 milliseconds (ms) (CTCAE grade 1) using the specific/usual choice by [CONTACT_591725]. 7. A known history of additional risk factors for Torsades de Pointes (TdP) (e.g., congestive heart failure, hypokalemia, known family history of Long QT Syndrome).   For inclusion criteria (Section 5.5.1) #4 and exclusion criteria (Section 5.5.2) #9, final review and determination will be made centrally.  The baseline CT or MRI scan will be uploaded to the Duke coordinating center for final confirmation of eligibility.  Review the sponsor provided Imaging Manual 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 15 of 137 for more details about this transfer.  Once eligibility is confirmed the site will be notified.  Subjects will not be randomized until final eligibility is confirmed. 5.6 Risk/Benefit Assessment 5.6.[ADDRESS_780155] cognitive decline caused by [CONTACT_591726]/or reduction and/or remission of the subject’s HGG. Additionally, a potential benefit may include protection against development of thrombocytopenia caused by [CONTACT_591727]. From prior study of HGG, roughly 15% of patients will develop grade 3 or 4 thrombocytopenia [1]. These subjects are at risk for a bleeding complication and may have their cancer therapy interrupted to allow recovery of the bone marrow. If this can be prevented it would be a major advance in therapy for HGG.   Because this clinical protocol is experimental, it cannot be guaranteed that subjects will receive any benefit as a result of participating in this research study. The information collected in this research may help scientists better understand the mechanisms involved in oxidative stress as it pertains to treatment of brain cancer. If such an understanding emerges from this research, it may benefit society by [CONTACT_591728]. 5.6.[ADDRESS_780156] been performed using intravenous infusions of a related metalloporphyrin in multiple models including rats, mice, dogs, guinea pi[INVESTIGATOR_14107], and baboons with the finding of dose-related hypotension [2]. Metalloporphyrin compounds being evaluated are potent, catalytic antioxidants and have the potential to scavenge superoxide within the vascular system and thereby [CONTACT_591729]. This would augment the vasodilating activity of nitric oxide and lead to hypotension [2]. This has been found in animal models to be a significant, but transient side effect and therefore blood pressure monitoring is essential in this clinical trial of a metalloporphyrin compound. Studies of rats, mice, and monkeys have been performed with BMX-[ADDRESS_780157] shown transient, dose-related hypotension. Hypotension is related to plasma Cmax levels and subcutaneous administration significantly reduces the risk of this toxicity in mice and primates (unpublished data per BioMimetix JV, LLC). This hypotensive effect was also found in primates. We have designed this protocol to monitor blood pressure closely.  A summary of the possible adverse side effects that could be associated with BMX-[ADDRESS_780158] common side effects (expected to occur in more than 30% of subjects) are: • Red to brown discoloration of the skin at the injection site which may take up to several weeks to resolve • Irritation at the site of the injection of the drug under the skin • Transient tachycardia from study drug   Less common side effects (expected to occur in 10-30% of subjects) are: • Transient pain at the injection site.  This is expected to be related to the concentration of administered drug and the volume administered, rather than subject body size   • Local histamine release which could be caused by [CONTACT_5349]. This could cause pruritus (itching), erythema (redness), edema (swelling), urticaria (welts).  This is expected to resolve within a couple of hours of injection   
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 16 of 137 Rare side effects (expected to occur in less than 10% of subjects) are: • Temporary hypotension (low blood pressure) • Malaise or “not feeling well” for a few hours • Prolongation of the QTc interval   Additional possible side effects: • Light-activated skin rash in response to sun exposure (not yet reported in humans) • Red to dark color of urine (not yet reported in humans) • It is also possible that previously unobserved and unexpected side effects could occur. Human safety data for BMX-001 in combination with TMZ and RT has been studied in Phase 1 of this clinical trial. BMX-001 at 42 mg/subject loading dose and 20 mg/subject subsequent doses given twice weekly was the maximum administered dose and 28 mg/subject loading dose and 14 mg /subject for subsequent twice weekly doses was the MTD. Sinus tachycardia (grade 3) was the dose-limiting toxicity at 42 mg/subject loading dose (n=1). The only other related grade ≥ 3 event seen was hypotension (grade 3) (n=1). The most common related toxicity was grade 1 injection site reaction (n=7). There is no apparent toxicity to end organ tissues or bone marrow. 5.6.[ADDRESS_780159] common side effects (occurring in more than 30% of subjects): • Fatigue  • Nausea • Hair loss  Less common side effects (occurring in 10-30% of subjects): • Thrombocytopenia (low platelets), which may result in easy bruising or bleeding for a longer time. • Loss of appetite • Headache • Constipation • Diarrhea • Vomiting • Rash • Swelling in extremities  Rare side effects (occurring in less than 10% of subjects): • Abdominal and/or breast pain • Dry skin, skin redness, and/or itching • Inflammation of the mouth, throat and/or sinuses • Dizziness, weakness • Confusion, memory impairment • Anxiety, depression • Joint and muscle pain • Trouble sleepi[INVESTIGATOR_007] • Change in sense of taste • Blurred vision • Coughing or shortness of breath • Urinary incontinence/frequency, urinary tract infection • Weight increase • Seizures/convulsions • Adrenal hypercorticisim (elevated hormone levels) 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 17 of 137 • Low white blood cell (WBC) count, which may lead to infection. • Allergic reaction, sometimes severe • Anemia (decreased number of red blood cells), which may cause symptoms of shortness of breath, weakness, and fatigue.  Rarely, unusual (“opportunistic”) infections have occurred. Rare cases of erythema multiforme (skin condition) have been reported, which got better after TMZ was stopped and, in some cases, recurred upon restarting treatment with TMZ.  Very rare side effects have included secondary cancers including leukemia and myelodysplastic syndrome (MDS). MDS is a disorder of the bone marrow in which blood cells that do not function normally are produced.  There have been reports of hepatotoxicity or liver injury in patients receiving TMZ. TMZ may cause elevations in liver enzymes, which measure liver function, elevation of bilirubin levels, which may lead to jaundice or a yellowing of the skin and mucous membranes, cholestasis, which results from a decreased flow of bile from the liver, and hepatitis, an inflammation of the liver.  Reproductive studies have not been done with TMZ. Immature sperm and testicular atrophy (wasting away) occurred in studies with rats and dogs, using doses of TMZ 1/4 and 5/8 of the recommended human doses. In animal studies, TMZ caused death and multiple malformations in rats and rabbits exposed during pregnancy. 5.6.4 Radiation Treatment Side Effects Possible side effects include swelling of the brain, hair loss, localized skin irritation, low blood counts, fatigue, memory loss, hearing loss, nausea and/or vomiting, loss of appetite, headaches, RT necrosis (death of tissue or skin), and secondary cancer. 5.6.[ADDRESS_780160] (a professional trained to draw blood). 5.6.6 Risks of MRI Risks and/or discomforts associated with MRI scans include anxiety produced from being in a tight, enclosed space (claustrophobia). In addition, the machine operates using a large and powerful magnet, which attracts certain metals. Therefore, people with metals in their bodies that are not compatible with MRI will be excluded from the study. Patients will also be checked to make sure that they do not bring any metal objects into the MRI facility. Dental fillings are less affected by [CONTACT_570070]. It will be asked that patients let the physicians conducting this study know of any metal in their bodies other than dental fillings. During the MRI, patients will be given a contrast agent. The agent is given routinely to obtain enhanced MRI scans of the brain. The agent is administered through the vein and requires the placement of an IV catheter. The catheter placement is similar to drawing blood except that the catheter remains in the vein during the time the agent is actively delivered. The risks of a blood draw and insertion of a catheter are similar. There have been a few, rare cases of allergies to the agent used in MRI contrast enhanced scans. Patients with any known severe allergies to contrast agents will be excluded from the study. Patients with mild allergies (i.e., rash only) may be pretreated with Tylenol and Benadryl prior to injection of the contrast agent. A rare but serious adverse reaction has been observed in patients that received a gadolinium-based contrast material during MRI examinations, a reaction called nephrogenic systemic fibrosis (NSF). Patients with kidney disease are at increased risk of 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 18 of 137 developi[INVESTIGATOR_248526]. NSF may cause skin thickening, joint pain and/or swelling. In rare cases NSF can lead to lung and heart problems and cause death. 5.6.7 Unknown Risks The overall risk classification of this research is unknown.  5.7 Data Analysis and Statistical Considerations Within the Phase 1 portion of this study, the MTD for BMX-001 administered in conjunction with temozolomide and radiation treatment will be determined for patients newly diagnosed with high grade glioma. A CRM model as described in section [IP_ADDRESS] will be used to determine the dose with the estimated DLT rate closest to the target DLT rate of 0.25. This Phase [ADDRESS_780161] stage involves dose escalation in successive cohorts of 3 patients until a DLT is observed. The second stage commences with the observation of a DLT. Within the second stage, all accumulated data will be used within the context of a one-parameter model to determine the appropriate dose for each subsequent cohort of 3 patients. When the toxicity outcomes associated with patients within a cohort within the second stage are known, the one-parameter logistic model will be re-estimated by [CONTACT_1758]’s statistical team using all available data. Based upon this re-estimated model, the dose level that results in a DLT rate nearest to the target DLT rate will be determined, and used to treat the next patients, subject to a dose escalation restriction. That restriction requires that the dose for the next patient cannot be more than one level higher than that of the current patient.  In Phase 2, the study’s primary endpoint is overall survival, defined as the time between randomization and death. A logrank test will be used to compare the survival experience of the two treatment arms. An intent-to-treat philosophy will be used in the analysis of survival by [CONTACT_591730]. Among the secondary endpoints are two that are of particular interest: cognitive function and thrombocytopenia. The mean change in cognitive functioning between baseline (enrollment) and week [ADDRESS_780162] will be conducted to compare the prevalence of such thrombocytopenia observed in patients with and without BMX-001 [1].    
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 19 of 137 6 STUDY SCHEMA 
  Figure 1: Study Schema for Phase [ADDRESS_780163] of study procedures.     

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 20 of 137 7 BACKGROUND AND SIGNIFICANCE 7.1 Study Disease Primary brain tumors represent 1% of all diagnosed cancers, but are among the most lethal [3]. Median survival for adults with HGG (WHO grade III and IV) is poor and ranges from 9-[ADDRESS_780164] of care for newly diagnosed high-grade gliomas (HGGs) involves surgical resection, followed by [CONTACT_591731], and subsequent adjuvant TMZ. Patients with HGG not only contend with oncologic diagnosis but also a neurologic one that can lead to cognitive dysfunction. 7.2 Radiation-Induced Damage during Brain Tumor Treatment During the disease treatment course, the nervous system can be damaged by [CONTACT_591732]. In particular, RT can lead to the generation of reactive oxygen species which in turn leads to oxidative stress [4]. The oxidative stress is not only responsible for the damaging of the DNA and killing of the tumor cells but also leads to damage of the white matter [5]. Central nervous system toxicity from RT is defined as acute, early delayed, and late delayed [6]. Acute form can occur during RT and is more apparent with doses > [ADDRESS_780165] chemoradiation in adult glioma patients. Early delayed encephalopathy and late delayed encephalopathy are still seen with some frequency in the HGG population. Early delayed encephalopathy is characterized clinically by [CONTACT_586372], attention deficits, and gait impairment. This occurs between one to six months after RT and is thought to be due to transient demyelination. Late delayed encephalopathy occurs months to years after RT and, clinically, patients demonstrate a pattern of subcortical dementia (short-term memory loss, problems with gait and attention). Mechanism of action involves damage to the supporting vasculature, which in turn leads to demyelination and, in severe cases, RT necrosis. The impact to patients is cognitive impairment and subsequent degradation of HRQoL. In fact, 50-90% of brain tumor patients that received RT demonstrated cognitive impairment, if they survived >6 months from RT [7-10]. In summary, the oxidative stress produced by [CONTACT_591733], subsequent cognitive impairment, and finally quality of life impairment.  7.3 Cognition and HRQoL in HGG Cognitive dysfunction, whether it develops due to the underlying tumor, treatment, or use of medications such as anti-epi[INVESTIGATOR_591694], usually comes in concert with a reduction in HRQoL. In both newly diagnosed and recurrent HGGs, reduction in cognitive function was associated with a reduction in reported HRQoL [11-13]. When compared to healthy controls or patients with other malignancies, high-grade glioma patients experience a great degree of cognitive impairment and related reduction in HRQoL [13].  Before and during treatment for HGG, adult patients experience a decline in perceived HRQoL[14,15]. Liu defines HRQoL as “a concept that encompasses the multidimensional well-being of a person and reflects an individual’s overall satisfaction with life” [15]. For brain tumor patients, focal neurological dysfunction, whether cognitive or physical, fatigue associated with treatment, symptoms such as nausea and anorexia associated with treatment, and other common symptoms such as insomnia, seizures, and headaches all have negative impacts on HRQoL. Overall, functionality and HRQoL are particularly important in brain tumor patients since these patients have more dysfunction in these areas than age-matched controls with non-small lung cancer [13]. In a large prospective study by [CONTACT_591734], they found that HRQoL, as rated by [CONTACT_591735], was low before starting any type of treatment, and factors associated with poorer HRQoL included patients with poor performance status, illiteracy, and a more aggressive nature of the tumors [16]. Moreover, HRQoL is dependent upon the physical function and cognition of the brain tumor patient such that patients with better physical function and better cognitive 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 21 of 137 function reported having a higher level of HRQoL [11]. Liu and colleagues discuss how these symptoms and signs are interrelated and should not be studied alone because cognitive decline/dysfunction were associated with increased fatigue and poorer performance status [15,17,18]. During concurrent chemoradiation, brain tumor patients experience a decline in relative HRQoL particularly due to fatigue and changes in cognition [7,19].   In order to capture fully the many aspects of cognition and HRQoL, we have utilized both objective and subjective measures to evaluate issues with cognition, fatigue, HRQoL, and mood. Cognition can be measured objectively with standardized cognitive testing. One testing model is CNS Vital Signs®, a computerized battery. CNS Vital Signs® has been validated and is being used extensively in our research, not only primary brain tumor patients, but also patients with other forms of cancer [20]. Modalities within CNS Vital Signs® assess cognitive flexibility, complex attention, executive functioning, psychomotor speed, processing speed, verbal and visual memory. We published the cognitive performance of newly diagnosed HGG using this battery and showed that they had measurable cognitive dysfunction in all domains [21,22]. After diagnosis, newly diagnosed HGG patients exhibit deficits in all tested cognitive domains with standardized scores ranging from 90.1 to 72.7 (a score of 100 represents mean standardized score for normative age-matched subjects). These deficits continue throughout the treatment and disease trajectory with lower performances present after radiotherapy and 24 weeks after initial diagnosis. Importantly, performance on neurocognitive testing is independent of education, grade, gender, and tumor location, but Karnofsky Performance Scale (KPS) and surgery extent are important predictors of neurocognitive performance. Moreover, long-term survivors of primary HGG (WHO grade IV) continued to exhibit cognitive dysfunction despi[INVESTIGATOR_591695] [23]. Therefore, there is an unmet need to improve the cognitive outcomes in patients with newly diagnosed HGG, irrespective of survival outcomes. Another testing model called The Brief Assessment of Cognition (BAC) is a battery of tests is implemented through an iPad-based app (VeraSci). The BAC was created by [CONTACT_591736], Jim Gold, Terry Goldberg, and Philip Harvey as a pen-and-paper measure for the repeated assessment of cognition in clinical trials for schizophrenia (referred to as BACS) [24]. With published normative data [25] and over a decade of use, the BACS is the subject of approximately 100 peer-reviewed papers and has been used in over 30 multisite clinical trials across a range of patient groups. To reduce rater burden and promote standardization of neurocognitive testing in clinical trials, the BAC is now implemented as an iPad-based app [26]. The BAC App assists raters in administration and scoring of all subtests included in the original pen-and-paper instrument.  Subjectively, HRQoL is measured using patient-reported outcome questionnaires known as PROs. A commonly used instrument is the Functional Assessment of Cancer Therapy-Brain (FACT-Br) which has been used extensively and has been documented to identify key QoL problems for brain tumor patients [27]. Other standardized questionnaires will include Functional Assessment of Cancer Therapy-Fatigue, Functional Assessment of Cancer Therapy-Cognition, and Beck Depression Inventory.  RT in patients with HGG causes oxidative stress in brain tissue, which can lead to white matter damage, subsequent cognitive impairment, and HRQoL impairment. White matter damage due to RT can be detected using serial MRI diffusion tensor/susceptibility imaging [28-30]. This damage is evident and detectable using serial MRI diffusion tensor/susceptibility imaging both immediately and subsequently after the completion of RT in HGG patients [31-33]. Therefore, MRI diffusion tensor/susceptibility imaging can serve as a biomarker of white matter damage caused by [CONTACT_591737]. In fact, early changes in the parahippocampal white matter seen on MRI diffusion tensor/susceptibility imaging have been linked to late decline in verbal memory in patient that received RT [34].   Interventions to improve cognition and HRQoL in brain tumor patients have included stimulants such as methylphenidate and modafinil. Clinical trials with methylphenidate in brain tumor patients 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 22 of 137 undergoing RT were discontinued in early stages because interim analysis did not show any evidence of effectiveness [35]. Studies with modafinil did show some positive effects on HRQoL in brain tumor patients, but the study was not placebo-controlled [36]. Medications to treat Alzheimer’s disease are being explored in the glioma population. Donepezil, a reversible acetylcholinesterase inhibitor used in mild to moderate Alzheimer’s dementia, has been studied in primary brain tumor patients. In this Phase 2 study, donepezil improved cognition, mood, and HRQoL in irradiated brain tumor patients [37]. More rigorous Phase 2 studies are needed to evaluate the effectiveness of anti-Alzheimer’s agents in glioma patients and side effects from these medications have limited their usefulness. Therefore, new approaches and more clinical studies are needed to evaluate interventions in regards to cognition and HRQoL in primary brain tumor patients.   In Phase 1, all fifteen subjects have completed quality of life evaluations and cognitive evaluations for the time points before concurrent chemoradiation and after concurrent chemoradiation. Cognitive testing included Hopkins Verbal Learning Test-Revised (HVLT-R), Trails Making A and B Tests, and Controlled Oral Wood Association Test (COWA). While it is early to assume cognitive protection of BMX-001, we have early findings that there is improvement of verbal memory as demonstrated by [CONTACT_591738]-R, and no degradation in performance on Trails Making B Test (Figure 2) and COWA. This is notable because these arethe primary cognitive tests that reveal poorer performance in HGG patients after RT.   
Figure 2. Performance on cognitive testing in 15 subjects in Phase 1 study of newly diagnosed high-grade glioma utilizing BMX-001 in combination with concurrent chemoradiation. Left panel: HVLT-R (higher scores = better performance). Right panel: Trails Making B Test (faster/shorter times = better performance) (note, only [ADDRESS_780166]) While promising, these results, along with the quality of life data, will need to be considered more fully after more subjects are treated with BMX-[ADDRESS_780167] of care is to stop therapy for patients developi[INVESTIGATOR_007] a platelet count below 100,000. None of the fifteen evaluable subjects receiving BMX-001 + temozolomide developed platelet counts below 100,000. We compared this to patients that were not on protocol but had a diagnosis of glioblastoma (GBM) and were receiving radiation and TMZ and were being treated at the Duke Cancer Institute. In this control cohort, 9 out of 20 patients who 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 23 of 137 received concurrent TMZ and radiation therapy developed thrombocytopenia with platelet counts below 100,000. While these groups cannot be directly compared, the observation that subjects that received BMX-001 along with concurrent chemoradiation did not develop platelet counts below 100,000/mm3 is compelling.  
 
 Figure 3. Platelet counts in high-grade glioma patients receiving temozolomide with and without BMX-001. Each line represents a separate patient. N=20 for patients receiving chemoradiation alone (left panel). N=15 for patients receiving BMX-001 + chemoradiation (right panel).  The data supports the conclusion that BMX-001 may be beneficial in preventing chemotherapy-induced bone marrow suppression at administered doses between 7 mg and 42 mg/subject load followed by [CONTACT_31806]-half the loading dose administered biweekly.  Of note, there are now current studies underway with BMX-001 in radiation protection for mucositis and xerostomia in irradiated head and neck cancer patients, as well as a therapeutic for patients with 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 24 of 137 multiple brain metastases. With the information from these studies, we are confident in our toxicity pattern for BMX-001 in cancer patients and in the doses chosen for Phase 2 evaluation.  7.5 BMX-001 It is well-established that induction of oxidative stress after RT and chemotherapy plays a major role in tumor and normal tissue therapy responses [38,39]. Ironically, the responses in tumor tend to protect vascular endothelium and tumor cells from RT damage [40], whereas these same stresses after RT promote normal tissue damage [38,41]. A variety of approaches have been investigated to mitigate oxidative stress post irradiation, including the free radical scavenger, amifostine [42-44]. Although this agent is approved for this use, its daily use is limited by [CONTACT_99766] [42,44]. Other agents that have been tested pre-clinically and clinically include nitroxides and genistein, but these are not currently approved for protection against normal tissue injury post irradiation, and neither provides catalytic inactivation of reactive species responsible for oxidative stress [42]. Over the past [ADDRESS_780168] developed a class of manganese (Mn) porphyrin-based compounds that: 1) are potent anti-inflammatory agents and 2) catalytically inactivate a range of reactive oxygen species, including peroxynitrite and superoxide anion [45-47]. These properties give this class of compound the unique function of protecting normal tissues while also augmenting tumor killing in patients undergoing radiation and chemotherapy. In addition to inactivation of reactive oxygen species, these drugs inhibit transcriptional activity of stress-induced transcription pathways by [CONTACT_591739]. Transcription factors known to be inhibited by [CONTACT_591740]-1 [48,49], NFĸB [50], SP-1 [51] and AP-1 [45]. The most recently developed compound, BMX-001 (MnTnBuOE-2-PyP5+), is among the most highly potent in a series of well over two dozen metalloporphyrins that have been evaluated thus far [52]. BMX-[ADDRESS_780169] a range of CNS conditions associated with inflammation, including stroke [53] and spi[INVESTIGATOR_260833] [54-56]. Furthermore, metalloporphyrins have been shown to protect mice from total body irradiation toxicity [57] and xerostomia following parotid gland irradiation [58]. Radiation-induced lung injury was protected against by [CONTACT_591741] [59]. Relevant to this application, Weitzel and colleagues showed protection against hippocampal stem cell loss and white matter degradation after whole brain RT therapy [58]. In this study, C57BL/6J mice were exposed to 8 Gy of whole brain irradiation with and without concurrent BMX-001. In mice that had been treated with BMX-001 and RT, there was preservation of myelin in the corpus callosum and anterior commissure in comparison to mice that received only RT without BMX-001. Moreover, the mice that received BMX-001 and RT performed better on rotorod tests and running wheel tests, both tests of cognitive function, in comparison to the RT alone group. It is well-established that oxidative stress and cognitive losses are a consequence of brain irradiation [6]. Therefore, there is ample evidence to suggest that BMX-001 will reduce the magnitude of oxidative stress after RT therapy and TMZ; this will lead to protection against cognitive losses and improvement in HRQoL.  In tumors, [CONTACT_591784] and colleagues showed that RT and chemotherapy increase oxidative stress, driving upregulation of HIF-1 [40,60], a transcription factor that promotes endothelial and tumor cell survival and increases tumor aggressiveness [61]. Radiation creates persistent oxidative stress in surviving cells, which upregulates NFkB [62]; this transcription factor also drives treatment resistance [63]. Treatment with this new class of metalloporphyrin prevents HIF-1 and NFkB upregulation in tumors after RT and chemotherapy and improves tumor treatment responses [57]. Using LN-[ADDRESS_780170] on clonogenic survival when 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 25 of 137 cells were also exposed to RT [64]. The effect of BMX-001 has been studied on mouse flank HGG xenografts. In this study by [CONTACT_591742], while RT did lead to a reduction in GBM tumor growth in comparison to saline alone, the combination of BMX-001 and RT demonstrated a greater and significant degree of tumor reduction [64]. This demonstrated that BMX-[ADDRESS_780171] dosing of 75 mg/m2. We have confirmed that BMX-001, when added to standard RT and TMZ, will be safe at pharmacologically relevant doses in patients with newly diagnosed HGG. Safety and MTD have been determined in the Phase [ADDRESS_780172] bone marrow from chemotherapy-induced thrombocytopenia.   
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 26 of 137 8 OBJECTIVES AND ENDPOINTS Table 1: Phase 1 Objectives and Endpoints  Objective Endpoint Analysis Primary To determine the maximum tolerated dose (MTD) of BMX-[ADDRESS_780173] RT and TMZ in newly diagnosed HGG patients Proportion of patients with DLT See Section [IP_ADDRESS] Secondary To examine the impact on cognition of BMX-[ADDRESS_780174] RT and TMZ in treatment of newly diagnosed HGG patients Mean change between baseline and week 24 in normalized scores for cognition using standardized cognitive tests and computerized battery CNS Vital Signs®. This includes Hopkins Verbal Learning Test-Revised, Trails Making Test Parts A and B, and Controlled Word Association Test and CNS Vital Signs® battery consisting of seven tests that measure verbal and visual memory, finger tappi[INVESTIGATOR_007], symbol digit coding, the Stroop Test, a test of shifting attention, and continuous performance test.  See Section [IP_ADDRESS] 
Secondary To assess the efficacy of BMX-[ADDRESS_780175] RT and TMZ in newly diagnosed HGG patients based upon overall survival (OS) and progression free survival (PFS)  Median OS, where OS is defined as the time to death from the time of protocol treatment is initiated Median PFS, where PFS is defined as the time between initiation of protocol treatment and the first recurrence of disease or death  See Section [IP_ADDRESS] Secondary To describe radiographic response in newly diagnosed HGG patients treated with BMX-[ADDRESS_780176] RT and TMZ Proportion of patients with radiographic response See Section [IP_ADDRESS] Secondary To characterize the pharmacokinetic profile of BMX-001 when delivered in combination with RT and TMZ in newly diagnosed HGG patients Plasma concentrations and calculated pharmacokinetic parameters (maximum concentration, time to reach maximum concentration, area under the curve, half-life, total body clearance, and volume of distribution) will be determine for BMX-[ADDRESS_780177] RT and TMZ Mean change from baseline at each follow-up assessment for subscales of the following PROs include Functional Assessment of Cancer Therapy-Brain Cancer (FACT-BR) version 4, Functional Assessment of Cancer Therapy-Fatigue (FACIT-Fatigue) subscale, version 4, Functional Assessment of Cancer Therapy-Cognition (FACT-Cog) subscale, Beck depression inventory (BDI-II), revised version, Godin Leisure questionnaire See Section [IP_ADDRESS] 
Exploratory To describe changes in hair loss during BMX-[ADDRESS_780178] RT and TMZ in newly diagnosed HGG patients Subjective investigator and patient assessment, photographs See Section [IP_ADDRESS]    
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 27 of 137 Table 2: Phase [ADDRESS_780179] RT and TMZ alone in newly diagnosed HGG patients based upon overall survival (OS).  Median OS, where OS is defined as the time to death from randomization. See Section 16.5.[ADDRESS_780180] and BAC (VeraSci) consisting of seven tests that measure verbal memory and learning, working memory, motor function, verbal fluency, speed of processing, and executive function.  See Section 16.5.[ADDRESS_780181] RT and TMZ treatment and who had suspension of TMZ therapy.  See Section [IP_ADDRESS] 
Secondary To assess the safety and tolerability of standard RT and TMZ in combination with BMX-[ADDRESS_780182] RT and TMZ alone in newly diagnosed HGG patients based upon progression-free survival (PFS). Median PFS, where PFS is defined as the time between initiation of protocol treatment and the first recurrence of disease or death. See Section 16.5.[ADDRESS_780183] RT and TMZ alone. Proportion of subjects with complete or partial radiographic response. See Section 16.5.2 Secondary To characterize the repeated-dose pharmacokinetic profile of BMX-001 when delivered in combination with RT and TMZ in newly diagnosed HGG patients. Plasma concentrations and calculated pharmacokinetic parameters (maximum concentration, time to reach maximum concentration, area under the curve, half-life, total body clearance, and volume of distribution) will be determined for BMX-001. See Section 16.5.[ADDRESS_780184] RT and TMZ alone. Mean change from baseline at each follow-up assessment for subscales of the following PROs include Functional Assessment of Cancer Therapy-Brain Cancer (FACT-BR) version 4, Functional Assessment of Cancer Therapy-Fatigue (FACIT-Fatigue) subscale, version 4, Functional Assessment of Cancer Therapy-Cognition (FACT-Cog) subscale, Beck depression inventory (BDI-II), revised version, Godin Leisure questionnaire.  See Section 16.5.3 
Protocol #: BMX-HGG-[ADDRESS_780185] RT and TMZ alone.  MRI Brain Diffusion Tensor /Susceptibility Imaging (white matter integrity).  See Section 16.5.3   
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 29 of 137 9 INVESTIGATIONAL PLAN 9.1 Study Design  As this study is a Phase 1/2 study, this protocol includes a Phase 1 Dose Escalation portion and a randomized Phase 2 portion. In the Phase 1 Dose Escalation portion of the study, the dose of BMX-001 will be escalated, while the dose of daily TMZ and RT (chemoradiation phase) will remain fixed and will be followed by [CONTACT_591743] (adjuvant phase). The randomized Phase [ADDRESS_780186] on cognition and on bone marrow suppression.  A clinical research coordinator will schedule all of the appointments and the calendar will be provided to the patients. For study schema, please see Section 6 and Figure 1. 9.1.1 Phase 1 Specific Design This Phase 1 study will be a single-site study of escalating doses of BMX-001 in combination with RT and TMZ (chemoradiation phase), followed by [CONTACT_591743] (adjuvant phase). In the chemoradiation phase, external beam RT therapy will be given over less than seven weeks in 30-33 fractions for a total dose of 59-60 Gy. TMZ (75 mg/m2 po daily) will be started on the first day of RT and will be administered for [ADDRESS_780187] undergone treatment without experiencing a DLT after a monitoring period of four weeks following completion of all doses of BMX-001, the dose of the subsequent group of 3 patients will be escalated. [IP_ADDRESS] Dose Escalation for BMX-001 in Phase 1 BMX-001 will be administered subcutaneously as a loading dose before starting concurrent chemoradiation (days -5 through 0 depending on patient/radiotherapy scheduling). After the loading dose, the dose levels will be given two times per week for 8 weeks. The starting dose level will be 7 mg loading dose. BMX-001 dose escalation will be 7 mg loading dose, 14 mg loading dose, 28 mg loading dose, and 42 mg loading dose in four dose levels. After the loading dose, the BMX-001 dose will be administered at the amounts listed below twice a week (see Table 3 below). The corresponding volumes of BMX-001, Injection Solution 10 mg/mL associated with the loading doses are as follows (the equivalent dose for a 70 kg adult is also given): 0.7 mL/subject loading dose = 7 mg/subject and is equivalent to 0.1 mg/kg for [ADDRESS_780188] 1.4 mL/subject loading dose = 14 mg/subject and is equivalent to 0.2 mg/kg for [ADDRESS_780189] 2.8 mL/subject loading dose = 28 mg/subject and is equivalent to 0.4 mg/kg for [ADDRESS_780190] 4.2 mL/subject loading dose = 42 mg/subject and is equivalent to 0.6 mg/kg for [ADDRESS_780191] The corresponding maintenance doses would be equivalent to the following:  0.35 mL/subject dose = 3.5 mg/subject and is equivalent to 0.05 mg/kg for [ADDRESS_780192] 0.7 mL/subject dose = 7 mg/subject and is equivalent to 0.1 mg/kg for [ADDRESS_780193] 1.4 mL/subject dose = 14 mg/subject and is equivalent to 0.2 mg/kg for [ADDRESS_780194] 2 mL/subject dose = 20 mg/subject and is equivalent to 0.3 mg/kg for [ADDRESS_780195] 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 30 of 137 BMX-001 will be administered by [CONTACT_127934] a sterile 10 mg/mL solution in saline. Syringes will be either 1 mL or 3 mL with a 25 gauge X 5/8 inch needle depending on the volume of injection. The subcutaneous injections may be at any optimum site on the torso, the upper leg or upper arm. Sites of injection should be alternated. Subsequent (maintenance) doses will be one-half the size of the loading dose (except Group IV where the subsequent dose is rounded down to 20 mg) and should be administered twice weekly. The first dose should be delivered 3 to 5 days after the loading dose and further doses delivered at 3 to 4 day intervals to average 2 doses per week. The BMX-001 doses other than the loading dose will be delivered within 12 hours before or after RT. Schedule of subsequent doses will be dependent on the day of the loading dose and radiation schedule. For each week the doses are given, the days will either be Monday and Thursday for injections or Tuesday and Friday for injections. BMX-001 will not be administered on Saturday or Sunday.   Table 3: Loading Doses and Subsequent Doses for BMX-[ADDRESS_780196] Group  I II III IV  Loading Dose1  7 mg 14 mg 28 mg 42 mg Week Subsequent Doses1 1 3.5 mg b.i.w. 7 mg b.i.w. 14 mg b.i.w. 20 mg b.i.w. 2 3.5 mg b.i.w. 7 mg b.i.w. 14 mg b.i.w. 20 mg b.i.w. 3 3.5 mg b.i.w. 7 mg b.i.w. 14 mg b.i.w. 20 mg b.i.w. 4 3.5 mg b.i.w. 7 mg b.i.w. 14 mg b.i.w. 20 mg b.i.w. 5 3.5 mg b.i.w. 7 mg b.i.w. 14 mg b.i.w. 20 mg b.i.w. 6 3.5 mg b.i.w. 7 mg b.i.w. 14 mg b.i.w. 20 mg b.i.w. 7 3.5 mg b.i.w. 7 mg b.i.w. 14 mg b.i.w. 20 mg b.i.w. 8 3.5 mg b.i.w. 7 mg b.i.w. 14 mg b.i.w. 20 mg b.i.w. 1Dose of BMX-001 for Injection, 10 mg/mL administered to subject. [IP_ADDRESS] Definition of Dose-Limiting Toxicity (DLT) Toxicities will be graded according to the NCI CTCAE version 4.03 criteria. DLTs will be defined as any of the following events that are possibly, probably, or definitely attributable to BMX-001 during dose escalation.  A dose limiting toxicity is defined as an adverse event or laboratory abnormality that is: a. assessed as unrelated to disease progression, intercurrent illness, or concomitant medications; b. occurs during and/or following the first dose of BMX-001; and c. meets any of the following criteria: [IP_ADDRESS].[ADDRESS_780197] anti-emetics; and grade [ADDRESS_780198] lipid-lowering agents. 2. > 14 day delay to re-treat due to failure to resolve any grade 3 or greater non-hematologic drug-related toxicity to re-treatment criteria or pre-treatment baseline. 3. Grade ≥ 2 neurological toxicity that impairs activities of daily living and persists ≥ 7 days. 4. Inability to complete > 75% of the planned RT treatments.  [IP_ADDRESS].2     Hematologic Occurrence of any of the following hematologic adverse events will be defined as a DLT: 1. Grade 4 neutropenia (ANC, including bands, ≤0.5 x 109 /l); 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 31 of 137 2. Grade 3 thrombocytopenia (platelet count of ≤ 50x109/l); 3. > 14 day delay to re-treat due to failure to resolve hematologic toxicity to re-treatment criteria. [IP_ADDRESS].3     Other Considerations Not applicable [IP_ADDRESS] Dose Modification There are no reductions in the BMX-001. If adverse events occur that require holding BMX-001, the dose will remain the same once treatment resumes.  Any toxicity possibly, probably, or definitely associated with BMX-[ADDRESS_780199] to proceed on study. Subjects who experience a Grade 3 or 4 allergic reaction / hypersensitivity, adult respi[INVESTIGATOR_1505], or bronchospasm (regardless of grade) will be discontinued from BMX-[ADDRESS_780200] of daily TMZ and RT with BMX-001 and Arm B will include daily TMZ and RT alone.  For the Phase 2 Study, BMX-001 will be administered subcutaneously as a loading dose before starting concurrent chemoradiation (days -5 through 0 depending on patient/MRI scheduling), during treatment, and after treatment concludes. After the loading dose, the subsequent doses will be given two times per week for 8 weeks. The BMX-001 doses other than the loading dose will be delivered within 12 hours before or after RT. Patients will be randomized with a treatment arm allocation ratio of 1:1 to receive BMX-001 or to proceed with RT and TMZ alone. There will be 160 patients enrolled in this phase of the study (80 subjects per arm). The Phase 1 trial has confirmed the safe RP2D for BMX-001. The loading dose determined safe from Phase 1 and being studied in Phase 2 is 28 mg/subject and the maintenance doses are each 14 mg/subject.  BMX-001 will be administered by [CONTACT_127934] a sterile 10 mg/mL solution in saline. The subcutaneous injections may be at any optimum site on the torso, the upper leg or upper arm. The first subsequent dose should be delivered 1 to 5 days after the loading dose and subsequent doses delivered at 3 to 4 day intervals to average 2 doses per week.  The Phase 2 criteria for holding, re-treating and discontinuing BMX-001 is captured in Section 13.4 BMX-001 Treatment Criteria.   9.1.3 Safety Considerations In Phase 1, no hypotension was found in the dose chosen for Phase 2. However, because of the development of transient hypotension in rat models, patients will undergo monitoring before and at 5 (+/-2), 15 (+/-3), 30 (+/-5) , and 60 minutes (+/- 5) minutes after the BMX-001 injections on the loading dose day and 5 (+/-2), 15 (+/-3), 30 (+/-5) on all other days of BMX-001 injections. This will 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 32 of 137 include the following vital signs: heart rate, oxygen saturation, and blood pressure. Injection site reaction will also be reviewed. In summary, patients will be observed for at least 60 (+/-5) minutes after the subcutaneous injection of BMX-[ADDRESS_780201] 30 (+/- 5) minutes on the maintenance dose days.   This observation will include collection of heart rate, oxygen saturation, blood pressure, as well as injection site reaction.   In primate studies, the primary toxicity seen was skin reaction/irritation and/or transient skin discoloration due to subcutaneous injection. Excretion of the drug was also associated with a red/purple color of urine. Care will be taken to limit the volume of the injections to no more than 1.4 mL per site. Thus a 28 mg/subject (2.8 mL @ 10 mg/mL) or 20 mg/subject (2 mL @ 10 mg/mL) dose will be administered in two equal portions at two different sites. A 42 mg/subject (4.2 mL @ 10 mg/mL) dose will be administered in three equal portions at three different sites. A separate drug product vial, syringe and needle will be used for each injection. Before patients are initiated on any treatments (radiation, TMZ, or BMX-001), patient must be at least 2 weeks from neurosurgical procedure (craniotomy, open biopsy, or stereotactic biopsy). Moreover, there can be no signs of wound-healing problems or infection at the craniotomy/biopsy site.  9.1.[ADDRESS_780202] been reports of human subjects with a QT prolongation present after a BMX-001 loading dose (28 mg/subject) that was not present at baseline.  Prolongation of QTc interval has not been observed in preclinical studies of BMX-001.    In all cases Electrocardiogram QT corrected interval prolonged did not exceed a grade 2 (average QTc 481 - 500 ms) according to CTCAE.  No action with regards to BMX-[ADDRESS_780203] develops prolonged QT after receiving a dose of BMX-001, the case should be reviewed with the BioMimetix Medical Monitor to determine further dosing of BMX-001 and inclusion in the study.  Additionally, levels of electrolytes (potassium, calcium, and magnesium) should be checked and supplementation given to correct any values outside the normal range.  Finally, concomitant therapi[INVESTIGATOR_591696]-prolonging effects.  If the cause is not identified and the investigator believes it is appropriate, particularly if QTc remains elevated, study drug may be interrupted, and an ECG should be re-checked in approximately [ADDRESS_780204] observed or more frequently as clinically indicated. If QTc has recovered or improved and the investigator believes it is safe to do so, continuing BMX-001 therapy should be considered if previously held.  9.1.5 Missed Doses Regardless of the reason for withholding study drug treatment, the maximum allowable length of treatment interruption is 3 weeks. If BMX-001 is withheld for greater than 3 weeks, BMX-001 will be discontinued. If BMX-001 is discontinued for missed doses, the patient will remain on the study and all planned study endpoints will be assessed. Any missed doses should be made up at the end of treatment, so that the subjects complete the planned number of doses (which is 17).  Any missed doses of BMX-001 should be documented with the reason included.   
Protocol #: BMX-HGG-[ADDRESS_780205] additional systemic steroids such as to treat an allergic reaction, adrenal insufficiency, increased neurological symptoms, and/or increased intracranial pressure, then systemic corticosteroids can be added to control symptoms at the discretion of the treating physician and at the minimal effective dose deemed medically appropriate. Dexamethasone use is allowed in this study.  Topi[INVESTIGATOR_591697] a contraindication.  Standard anti-emetics, such as ondansetron, will be able to be used during TMZ therapy. Ondansetron is typi[INVESTIGATOR_44800] 30 minutes before TMZ.  Use of drugs known to lengthen QT intervals should be avoided or minimized when possible.  9.1.7 TMZ Treatment Plan TMZ is an oral alkylating agent which has demonstrated anti-tumor activity as a single agent in the treatment of recurrent glioma. As stated previously, Stupp et al.[65] have demonstrated an increase in efficacy of TMZ in combination with RT in the adjuvant treatment of primary malignant gliomas. In addition, the regimen was considered safe. Non-hematological grade 2 toxicities included: Fatigue (26%), other constitutional symptoms (7%), rash and dermatologic side effects (9%), infection (1%), vision (14%), and nausea and vomiting (13%). Grade 3 / 4 non-hematological toxicities occurred <10%: Fatigue (7%), other constitutional symptoms (2%), rash and dermatologic side effects (1%), infection (3%), vision (1%), and nausea and vomiting with a 5HT3-RA (<1%). Thus, this safe and standard regimen will be utilized in this protocol. During the chemoradiation phase, daily TMZ therapy will be calculated at a dose of [ADDRESS_780206]. During the adjuvant phase, 5-day TMZ therapy will be calculated at a dose of 150 or 200 mg/m2 and be administered the first [ADDRESS_780207] cannot tolerate the 5-day TMZ and is switched to metronomic TMZ (low-dose, continuous TMZ), they will remain on the study and will complete all planned study endpoints. Use of Optune device will be allowed during the adjuvant phase with TMZ per NCCN guidelines and subjects will complete all planned study endpoints. If a subject completes only 6 cycles of temozolomide (vs. 12 cycles), they will remain in the study and subjects will complete all planned study endpoints through the planned 12 cycle timeframe.  After that they will be continued to be followed for vital status.    9.1.8 Radiation Treatment Plan As detailed by [CONTACT_372783] [65] regimen, RT therapy will be administered as fractionated focal irradiation in daily fractions of 1.8-[ADDRESS_780208] of care.   [IP_ADDRESS] Dose Definition and Schedule  The external beam RT therapy (RT) plan will be determined at the discretion of the local RT therapi[INVESTIGATOR_372717]. It should begin 2-12 weeks after surgery. One treatment of 1.8-2.0 Gy will be given daily, 5 days per week, (30-33 fractions over less than seven weeks) for a total 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 34 of 137 of 59-60 Gy. All portals shall be treated during each treatment session. Doses are prescribed at the maximum dose line encompassing > 95% of the target volume. [IP_ADDRESS] Physical Factors  Treatment shall be delivered on megavoltage machines of energy ranging from 4 to 18 MV photons. Selection of the appropriate photon energy(ies) should be based on optimizing the RT dose distribution within the target volume and minimizing dose to non-target normal tissue. Photon energies > [ADDRESS_780209] one beam with energy < [ADDRESS_780210] 80 cm.  [IP_ADDRESS] Localization, Simulation, and Immobilization  The patient shall be treated in the supi[INVESTIGATOR_167724]. A head-holding device that is transparent to x-rays and provides adequate immobilization must be utilized at all times during planning and therapy to ensure reproducibility.  The initial target volume shall include the contrast-enhancing lesion and surrounding edema (if it exists) demonstrated on the pre-operative MRI plus a 2.0-cm margin. If no surrounding edema is present, the initial target volume should include the contrast-enhancing lesion plus a 2.5-cm margin. This primary target volume will be treated to 45-[ADDRESS_780211] 100% but no more than 110% of the dose at the prescription isodose line.  All RT will be planned and performed by [CONTACT_591744].   [IP_ADDRESS] Treatment Planning and Safety  Treatment plans may include opposed lateral fields, a wedge pair of fields, rotation, or multiple-field techniques, including intensity-modulated radiotherapy (IMRT) and volumetric-modulated arc therapy (VMAT). MRI-guided 3D treatment planning is necessary to assure accuracy in the selection of field arrangements. Isodose distributions for the primary and boost target volume are required on all patients, including those treated with parallel-opposed fields. A composite plan is required showing the respective target volumes. The inhomogeneity across the target volume shall be kept to a minimum. The maximum dose should be no higher than 112% of the prescription. Possible side effects include swelling of the brain, hair loss, localized skin irritation, low blood counts, fatigue, memory loss, hearing loss, nausea and/or vomiting, loss of appetite, headaches, RT necrosis (death of tissue or skin), and secondary cancer.  [IP_ADDRESS] Dose Limitations to Critical Structures The lens and cervical spi[INVESTIGATOR_167725]. The maximum dose to the optic apparatus (optic chiasm, optic nerves, eyes) must be limited to 54 Gy, and the brain stem limited to 60 Gy. 9.1.9 Randomization Within the Phase 2 portion of this study, patients will be randomized using a 1:[ADDRESS_780212] of care treatment consisting of TMZ and RT with BMX-001 (Arm A) or without BMX-
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 35 of 137 001 (Arm B). A permuted block randomization algorithm stratified by [CONTACT_479] (III / IV) and by [CONTACT_591745]. 9.[ADDRESS_780213] additional safety data from the completion of this Phase 1 trial in humans. In Phase 1, the DLT for BMX-001 administered at 42 mg loading dose and 20 mg maintenance dose was sinus tachycardia (grade 3) in one subject. The only other toxicity related grade > 3 event seen was hypotension (grade 3) in one patient. The most common related toxicity was grade 1 injection site reaction in 7 patients. The volume of subcutaneous injection will be limited to 1.4 mL per site. Thus a 28 mg/subject (2.8 mL @ 10 mg/mL) dose will be administered in two equal portions at two different sites. A separate drug product vial, syringe and needle will be used for each injection.  9.[ADDRESS_780214] the following HrQoL assessments by [CONTACT_648]:  -FACT-BR  -FACT-Cog  -FACIT-Fatigue -Beck Depression Inventory  -Godin Leisure Questionnaire  Mailed questionnaire will be sent with a cover letter and will be pre-labeled with the Subject’s Study ID Number.  Subjects will be asked not to include their names or return addresses on the package in order to limit the PHI sent by [CONTACT_2319]. 9.6 Early Study Termination This study can be terminated at any time for any reason by [CONTACT_456]. If this occurs, all subjects on study should be notified as soon as possible. Additional procedures and/or follow up should occur in accordance with Section 13.7.1, which describes procedures and processes for prematurely withdrawn patients and in accordance with Section 13.7.2.     
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 36 of 137 10 STUDY DRUG (BMX-001) 10.1 Names, Classification, and Mechanism of Action BMX-001, also known as MnTnBuOE-2-PyP5+ (manganese butoxyethyl pyridyl porphyrin), is a metalloporphyrin antioxidant that has anti-inflammatory, anti-oxidant and anti-tumor functions. A series of metalloporphyrins have undergone preclinical evaluation and BMX-[ADDRESS_780215] mammalian species is highly sensitive to an oxidative shift, there is a concern for blood pressure monitoring in studies of the metalloporphyrin compounds. Studies in Sprague-Dawley rats showed that intravenous delivery of metalloporphyrin could lead to transient hypotension [2]. In this same study, mice, guinea pi[INVESTIGATOR_14107], dogs, and baboons receive intravenous delivery of metalloporphyrins with less effect on blood pressure. BMX-001 was patented by [CONTACT_591746], LLC. Molecular structure is depi[INVESTIGATOR_6517] 4.  
Figure 4: BMX-[ADDRESS_780216] Formulation and Manufacture The drug will be supplied by [CONTACT_591747], LLC. The drug substance (1.2 kg of solid) was manufactured and stored according to cGMP by [CONTACT_578736], Inc. (AMRI). BioMimetix has contracted with AMRI (Glasgow) Ltd. to manufacture single dose vials of sterile BMX-001 for injection. Manufacturing will be conducted on AMRI's Flexicon FPC50W filling machine, which is dedicated for aseptic GMP manufacturing within a clean room suite. Manufacturing will include batch pre-filtration and aseptic filtration and filling in accordance with AMRI Glasgow's validated process. BMX-001 will be formulated as a solution in 0.9% saline at 10 mg/mL, aseptically filtered and filled to 2 mL in a 5 mL Type 1 clear glass vial, sealed with a 20 mm Flurotec serum stopper and flip off aluminum overseal.  A nitrogen overlay will be applied to each vial following filling and prior to stoppering.   
Protocol #: BMX-HGG-[ADDRESS_780217], and in-process weight checking. Release tests and specifications for BMX-001 for injection are currently under development, but will be established before manufacturing of the clinical batch commences. These will include sterility (USP <71>), bacterial endotoxins (USP <85>), particulate matter (USP <788>), appearance, color and clarity, pH, osmolality, assay and purity. The clinical batch of drug product will be placed on stability and tested for the duration of its use during the clinical trials. 10.2.2 Labels for BMX-001 for Injection, 10 mg/mL An exemplary label for the BMX-001 for Injection, 10 mg/mL is reproduced in Figure 5.  BMX-001 for Injection, 10 mg/mL Lot # P07715 Administer SQ, ≤1.4 mL/site. Caution:  New Drug – Limited by [CONTACT_591748]:  [CONTACT_591785], cell [PHONE_12271] Store at Room Temperature Figure 5: Exemplary Label for BMX-001 for Injection, 10 mg/mL 10.2.3 Syringe and Label for Administration of BMX-001 for Injection, 10 mg/mL A pharmacist will prepare the loaded syringe(s) and needle(s) that will be used for subcutaneous administration of the appropriate dose of BMX-001 for Injection, 10 mg/mL to the clinical subject.   In Phase 2, the loading dose is 28 mg/subject and the maintenance doses are 14 mg/subject biw. The drug product is shipped to the clinical centers as a sterile solution of BMX-[ADDRESS_780218] be followed.   No more than 1.4 mL is to be administered at a single injection site. Thus a 28 mg or 20 mg dose will be administered in two equal portions (14 mg or 10 mg, respectively), taken from different vials and injected via separate syringes and needles at two different sites. A [ADDRESS_780219] cartons. The carton label includes the information indicated in Figure 6, where "XXX" is replaced by [CONTACT_591749]. Lot # P07715  Store at Room Temperature BMX-001 for Injection, 10 mg/mL Multi-Dose Kit Contents:  XXX Single-Dose Units @ 20 mg each Caution:  New Drug – Limited by [CONTACT_591748]:  [CONTACT_591785], cell [PHONE_12271] 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 38 of 137 Figure 6: Exemplary Label for Multi-Dose Kits 10.3 Supply, Receipt, and Storage The multi-dose kits described in Section 10.2.4 will be shipped by [CONTACT_591750]. These kits will be stored at room temperature per the Certificate of Analysis provided in the BMX-001 Investigator Brochure, in a locked, physically secure environment, according to the pharmacy's standard procedures for storage of investigational drug products. Drug accountability records will be maintained by [CONTACT_591751]. 10.4 Compliance and Accountability Drug accountability records will be maintained for all clinical trial supplies. 10.5 Disposal and Destruction All empty and partially used clinical trial supplies will be destroyed in accordance with the institution’s requirements for an investigational agent.  Unused supplies must not be destroyed until after drug accountability is performed by [CONTACT_591752]. Disposition of all unused boxes of study drug will be carried out according to instructions provided by [CONTACT_591747], LLC, at the end of the study after drug accountability is performed. The pharmacy will maintain detailed documentation of the number and identification of BMX-001 vials which are destroyed, and copi[INVESTIGATOR_591698], LLC.   
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 39 of 137 11 STUDY DRUG (TMZ) 11.1 Description 8-Carbamoyl-3-methylimidazol[5,1-d]-1,2,3,5-tetrazine-4-(3H)-one, CCRG [ZIP_CODE], M&B [ZIP_CODE])-Temozolomide is commercially available and not provided in this study.  11.2 Formulation TMZ is available in 250 mg, 180 mg, 140 mg, 100 mg, 20 mg, and 5 mg strengths. Refer to package insert for contents of the formulation.  11.3 Storage TMZ capsules should be stored between 2oC to 30oC. Commercial supply and packaging will be used. 11.4 Administration TMZ is administered orally on an empty stomach. The drug is approximately 100% bioavailable.  The dose will be rounded to the nearest [ADDRESS_780220]’s primary neuro-oncologist and the following can be taken into account: number of pi[INVESTIGATOR_591699]-payments required. Effects of food on product absorption are not yet known. DO NOT OPEN CAPSULES. DO NOT MIX WITH FOOD. DO NOT CHEW CAPSULES.  TMZ at a dose of 75mg/m2 po daily will be started with external beam RT (+/- 5 days). TMZ will be held according to standard of care for the institution (typi[INVESTIGATOR_591700] 100,000 cells/uL), grade 4 neutropenia, or grade 4 non-hematologic toxicity secondary to TMZ. TMZ will be re-started at 50 mg/m2 after resolution of the toxicity, or < grade 1. If the grade 3 thrombocytopenia, grade 4 neutropenia, or grade 4 non-hematologic toxicity secondary to TMZ recurs at 50 mg/m2, TMZ will be held during RT therapy, but may resume after RT therapy if the patient meets the treatment criteria.  11.[ADDRESS_780221] of inclusion and exclusion criteria.   
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 40 of 137 13 SCREENING AND ON-STUDY TESTS AND PROCEDURES Table 4: Screening and On-Study Tests and Procedures On-Study Tests and Procedures    Week [ADDRESS_780222] Evaluation Screeninga  Day -5 to 0 p          Adjuvant Phaseb, g, v Informed consent and Demographics w X           Randomization o X           History and physical exam, including full neurologic exam & KPS c X X  X  X  X  X Xb Vital signs, including blood pressure m X Xl Xl X Xl X Xl X Xl X Xb CBC with differential d X   X  X X X X X X  Xb CMP  X   X X X X X X X Xb PT, aPTT X           Beta-HCG, if applicable, within 48 hours prior to start of study treatment X           ECG X Xe Xe   Xe      PK sampling serum f  X  X   X     MRI of the brain X          Xb MRI (DTI/Susceptibility Imaging) in Phase 2 only  X         Xh BAC App Cognitive Testing s X (baseline)          Xb, s Additional Cognitive Testingg , t X (baseline)          Xb HRQoL Measurementsg X (baseline)          Xb Hair Loss Evaluationu X (baseline)          Xb Toxicity Assessment X Ongoing Xi Radiation   Continuous Dosing Monday-Friday for 6 weeks   TMZ   Continuous Dosing at 75 mg/m2 for 42 days  Will start adjuvantb BMX-001  Xj Xk Xk Xk Xk Xk Xk Xk Xk  a Within 3 weeks of starting BMX-001.  b Will transition to 5-day TMZ dosed at 150-200 mg/m2 po daily for the 1st 5 days in 28-day cycle (Adjuvant Phase). Study assessments for HRQoL Measurements, and Hair Loss Evaluation will be obtained approximately every 8 weeks (+/- 2 weeks) when a subject returns for a Standard of Care visit, until tumor progression, death, or patient comes off of study.  Cognitive testing will also be completed every 8 weeks and at SOC visits; Cognitive testing will continue after tumor progression.  CBC with differential will be obtained approximately on Days [ADDRESS_780223] of care scheduling for patient visits. 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 41 of 137 d Weekly CBCs and CMPs will begin at week 2 and continue through week 8. Platelet count is part of CBC with differential count.  e ECG will be done at screening for all subjects.  For subjects in Arm A, ECG will also be obtained before the loading dose is administered (within 5 to 60 minutes before the dose), and at 60 (+/- 15 min) minutes after the loading dose.  Pre-dose (within 5 to 60 minutes before the dose), and Post-dose ( 60 +/- 15 min) ECGs will also be collected at the Week [ADDRESS_780224] of Care visit during the Adjuvant Phase. These assessments should be completed prior to other study-related evaluations at study visits, if at all possible.  h DTI/Susceptibility Imaging is for clinical centers selected by [CONTACT_591753], during the Adjuvant Phase before the start of the first cycle of adjuvant temozolomide, as well as 6 months (approximately 24 weeks, +/- 2 weeks) after radiotherapy/chemotherapy  i Toxicity assessment will continue to be obtained at every SOC clinic visit during the Adjuvant Phase for a minimum of [ADDRESS_780225] chemo/RT for subjects not receiving BMX-001, and also followed for any unresolved adverse events considered related to study therapy.  j For BMX-001, this dose will be the loading dose. In Phase 2- Applicable only for patients in Arm A. k For BMX-001, doses (50% of the loading dose) will be twice a week subcutaneously weeks 1-8. There will only be two doses per week regardless of being a loading or maintenance dose. In Phase 2- Applicable only for patients in Arm A. l For patients in Phase 2 Arm B (standard RT + TMZ without BMX-001), vital sign evaluation will only be required on days of the History and Physical assessment.  m Arm A:  Patients will be monitored at drug administration with vital signs and injection site reaction at pre dose, at 5 (+/-2), 15 (+/-3), 30 (+/-5), and 60 (+/- 5) minutes post administration on the BMX-001 loading dose. Patients will be monitored at drug administration with vital signs and injection site reaction at pre dose, at 5 (+/-2), 15 (+/-3) and 30 (+/-5) minutes post administration on BMX-001 maintenance injection days. See Section 0.  o Phase 2 only, subjects will be randomized after all eligibility criteria is confirmed.   p For Phase 2: For subjects in Arm A, this column is the day of the BMX-[ADDRESS_780226] a Week 1 study visit, although they will be in the clinic for the start of RT and TMZ.   s These assessments should be completed prior to other study-related evaluations at study visits, if at all possible.  CNS Vital Signs®(Phase 1) /NeuroCog BAC App (Phase 2) will be done screening (baseline), and then approximately every [ADDRESS_780227]-Revised (Forms 1, 2, and 3), Trails Making Test Parts A and B, and Controlled Word Association Test will be performed only at baseline, the standard of care visit before the start of the first cycle of adjuvant temozolomide, and the standard of care visit that is 6 and 12 months from the completion of radiotherapy/chemotherapy.   See appendices for appropriate versions of these forms to use.   u  Hair loss evaluation includes subjective description and photos. v Patients will continue to complete visits in the adjuvant cycle for up to the [ADDRESS_780228] progression on MRI (even if they stop taking adjuvant TMZ).  Cognitive testing will be completed even after progression is noted.   w Collection of Gender, Race, Ethnicity, Education completed, employment, and smoking status to be obtained at screening.  13.[ADDRESS_780229] data to be collected at the Screening Examination is listed in the table above and includes physical and neurological examination; vital signs and weight; ECG, laboratory studies (complete blood count with differential, complete metabolic panel, PT/aPTT, and beta-HCG); past medical history; and concomitant medications (including but not limited to steroids and anticonvulsants).  Additional 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 42 of 137 baseline testing will be completed for the following:  cognitive testing, HRQoL Measurements, and hair loss evaluation.    The screening MRI or CT scan will be uploaded to the Duke central core for final review of eligibility.  This will be required for all subjects. The clinical centers will be notified of the final determination of eligibility prior to the subject completing any study visit.       The pathology report used to determine eligibility, which includes any tumor markers will be redacted and uploaded to the sponsor electronic data capture system.    If a subject is found to be ineligible to participate in the study, the patient will not be randomized to a treatment arm and minimal records regarding the subject and the reason for screen failure will be retained. 13.2 Run-In Period Not applicable. 13.3 Chemoradiation Treatment Period (with and without BMX-001) The treatment period for BMX-[ADDRESS_780230] RT with BMX-001 (Phase 1 and Phase 2 (Arm A)) followed by 2 weeks of BMX-001 (Phase 1 and Phase 2 (Arm A)).  For subjects in Arm B, this period is six weeks of concurrent daily TMZ with standard RT followed by 2 weeks of no treatment.   For subjects in Arm B, they do not need to return to the clinical center for a study visit once TMZ and RT is complete for visits at Week 7 and Week 8.   13.4 BMX-001 Treatment Criteria  If adverse events occur that require holding BMX-001, the dose will remain the same once treatment resumes.  Missed doses should be made up at the end of treatment to achieve the total number of planned doses (17).  13.4.1 Phase 2 - Criteria for holding BMX-001 Non-Hematologic Criteria 1. The occurrence of non-hematologic grade 3 or greater adverse events considered to be possibly, probably, or definitely related to BMX-001 during treatment with BMX-001, excluding grade ≥ 3 alopecia and elevation in alkaline phosphatase, grade ≥ [ADDRESS_780231] anti-emetics; and grade ≥ [ADDRESS_780232] lipid lowering agents. 2. Intolerable ≥ Grade 2 Injection Site Reactions 3. ≥ Grade 2 electrocardiogram prolonged QTc interval  Hematologic Criteria 1. Grade 4 neutropenia (ANC, including bands, ≤ 500 cells /μl); 2. Grade 3 thrombocytopenia (platelet count of ≤ 50,000 cells/μl);  13.4.2 Phase 2- Re-treatment Criteria for BMX-001 Non-Hematologic 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 43 of 137 1. Resolution of any grade 3 or greater toxicity felt to be possibly, probably or definitely attributable to BMX-001 to grade 1 or pre-treatment baseline. 2. Resolution of Intolerable ≥ Grade 2 Injection Site Reactions to < Grade 1 3. Resolution of Grade 2 electrocardiogram prolonged QTc interval to baseline, or after review by [CONTACT_3211].  Hematologic 1. ANC ≥ 1,000 cells/μl 2. Platelets ≥ 50,000 cells/μl  13.4.3 Phase 2- Discontinuation Criteria for BMX-001 Inability to resolve any grade 3 or greater toxicity felt to be possibly, probably or definitely attributable to BMX-001 to grade 1 or pre-treatment baseline within 21 days.    For both non-hematologic and hematologic events, if any event requires holding BMX-001 > [ADDRESS_780233] comes off study for the following reasons: completion of all study tests/procedures, progressive disease, unacceptable toxicity, allergic reaction to TMZ, allergic reactions to BMX-001, non-compliance with study follow-up, or withdrawal of consent. Patient death due to progressive disease will not be reported as a SAE. It is the intent that all patients will be followed as long as possible for survival. See Section 13.7.[ADDRESS_780234](s) 13.7.[ADDRESS_780235] from the study at any time based on his/her discretion. Reasons for PI-initiated withdrawal may include, but is not limited to the following: - Adverse events - Abnormal laboratory values - Abnormal test procedure results - Protocol deviation - Administrative issues - Disease progression- Patients will still complete cognitive testing (HVLT-R, COWA, TMT, BAC App) after coming off for disease progression.  All other assessments will stop at the point of 
Protocol #: BMX-HGG-[ADDRESS_780236] medical history assessments will be conducted and recorded per institutional and sponsor guidelines.  13.8.2 Physical and Neurological Examinations Physical and neurologic examinations, vital signs (temperature, respi[INVESTIGATOR_697], blood pressure and pulse), height (screening only), weight and KPS must be performed at:  - screening - day of loading dose (Arm A in Phase 2) - two weeks after the completion of RT and TMZ - every standard of care (SOC) clinic visit (approximately every 8 weeks) during adjuvant TMZ - at the time of study completion  Additional physical and neurological examination may be performed every two weeks during standard RT and TMZ per the standard of care practice. More frequent examinations may be performed at the investigator’s discretion, if medically indicated.   a. Physical examination, vital signs, weight and height A complete Physical Examination (PE) will include a general physical examination of major body systems, temperature, respi[INVESTIGATOR_697], blood pressure, heart rate, body weight and height.  Height will be measured and documented at screening only.  Blood pressure should be measured per institutional guidelines.   b. Neurologic examination A complete neurologic examination will include assessment of level of consciousness, mental status, speech, cranial nerves, motor, sensory, coordination, reflexes, and gait. Follow-up evaluation of the neurologic examination will be based on any changes in the neurologic clinical examination from the previous exam. Changes should be unrelated to postictal state or other unrelated events such as infection. 13.8.3 Electrocardiogram (ECG) ECG will be done for screening purposes for all subjects.  For subjects in Arm A, a baseline ECG prior to BMX-001 administration will be completed and at 60 (±15) minutes after dosing on the loading day of BMX-[ADDRESS_780237] BMX-001 maintenance dose administration day during Week 1 and any 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 45 of 137 dose in Week 4 pre-dose and at 60 (±15) minutes after dosing.   Results will be filed in the source for each subject and redacted tracings will be uploaded to the sponsor electronic database.    13.8.[ADDRESS_780238] RT and TMZ (within 2 to 4 weeks) and every standard of care (SOC) clinic visit (approximately every 8 weeks) during adjuvant TMZ. Institutional standard operating procedure will be followed (see Protocol Appendix A, Section 19.1). The clinical centers will be provided with a Clinical Trial Radiographic Assessment Form (CTRAF) to aid them with the data collection required for the study.  A different form may be used with approval from the sponsor.  RANO criteria will be utilizing based on the modifications from Ellingson et al. [66]. In these criteria, particularly in regards to newly diagnosed subjects, the areas considered in determining comprehensive objective status in RANO criteria are target lesions (enhancing disease), new sites of measurable disease, neurological examination status, and corticosteroid usage and dose.  Complete Response (CR): Requires all of the following: 1. Disappearance of all enhancing measurable and nonmeasurable disease sustained for at least [ADDRESS_780239] scan exhibiting disappearance of all enhancing measurable and non-measurable disease is considered “preliminary CR”. If the second scan exhibits measurable enhancing disease with respect to the “preliminary CR” scan, then the response is not sustained, noted as “pseudoresponse”, PsR, and is now considered “preliminary PD” (note confirmed PD requires at least two sequential increases in tumor volume). If the second scan continues to exhibit disappearance of enhancing disease or emergence of non-measurable disease (less than 10mm bidimensional product), it is considered a durable CR and the patient should continue on trial until confirmed PD is observed. 2. Patients should be either off of corticosteroids or on physiologic replacement doses only. 3. Stable or improved neurological examinations.   Partial Response (PR): Requires all of the following 1.  Greater than or equal to a 50% reduction in the size (products of the largest perpendicular diameters) for all enhancing lesions compared with baseline, sustained for at least [ADDRESS_780240] scan exhibiting greater than or equal to a 50% decrease in the sum of the products of the perpendicular diameters of all measurable enhancing lesions compared with the baseline is considered “preliminary PR”. If the second scan exhibits PD with respect to the “preliminary PR” scan, then the response is not sustained, noted as pseudoresponse, PsR, and is now considered “preliminary PD” (note confirmed PD requires at least two sequential increases in tumor volume.) If the second scan exhibits SD, PR, or CR, it is considered a durable PR and the patient should continue on trial until confirmed PD is observed. 2. Patients should have either the same corticosteroid doses or on lower corticosteroid dose compared with baseline scan.	3. Stable or improved neurological examinations  Stable Disease: Evaluations that do not meet criteria for CR, PR or PD.  Progressive Disease: Defined as the following 1.  Greater than or equal to a 25% increase in the product of the largest perpendicular diameters of any enhancing lesion or any new enhancing tumor on MRI scans. The first scan exhibiting greater than or equal to a 25% increase in the sum of the products of perpendicular diameter of the enhancing lesions should be compared to the smallest tumor measurement obtained either at baseline (if no decrease) or best response (on stable or increasing corticosteroid dose) and is 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 46 of 137 noted as “preliminary PD”. If the second scan at least 4 weeks later exhibits a subseqeuent greater than or equal to 25% increase in the sum of products of perpendicular diameters of the enhancing lesions relative to the “preliminary PD” scan, it is considered “confirmed PD” and the patient should be discontinued from the study. If the second scan at least 4 weeks later exhibits SD or, PR/CR, this scan showing “preliminary PD” is noted as “pseudoprogression”, PsP, and the subject should remain on study until a second increase in tumor size relative to the PsP scan is observed. Of note, any new measurable (> 10 mm X 10 mm) enhancing lesion should not be immediately considered PD, but instead should be added to the sum of the bidimensional products representing the entire enhancing tumor burden.  2. In the case where the baseline or best response demonstrates no measurable enhancing disease (visible or not visible), then any new measurable (>10mm x 10mm) enhancing lesions are considered PD after confirmed by a subsequent scan ≥4 weeks exhibiting greater than or equal to a 25% increase in sum of products of perpendicular diameters relative to the scan first illustrating new measurable disease. The first scan exhibiting new measurable disease is noted as “preliminary PD”. If the second scan at least 4 weeks later exhibits a subsequent greater than or equal to a 25% increase in sum of products of perpendicular of enhancing lesions relative to the “preliminary PD” scan it is considered “confirmed PD” and the patient should discontinue therapy. If the second scan at least 4 weeks later exhibits SD, CR, PR, or becomes non-measurable, this scan showing “preliminary PD” is noted as “pseudoprogression”, PsP, and the subject should continue on study until a second increase in tumor size relative to the “preliminary PD”, or PsP, scan is observed. Note that any new measurable (>10mm x 10mm) enhancing lesions on the subsequent scan following the “preliminary PD” scan should not be immediately considered “confirmed PD”, but instead should be added to the sum of bidimensional products representing the entire enhancing tumor burden. 3.  Unequivocal and significant worsening neurological examination not attributable to other causes. 4. Of note, if there has been a major reduction in steroid dosage in the interval and the patient is felt to be clinically stable or improved, the proper assessment may be “indeterminate” and the therapy could be continued pending the next evaluation. 5. Failure to return for evaluation as a result of death or deteriorating condition.  Not Evaluable (NE): Progression has not been documented and one or more sites have not been assessed. 13.8.5 HRQoL HRQoL will be assessed by [CONTACT_33743]-Brain (FACT-BR) scale. The FACT-BR (version 4) contains subscales for physical (7-items), functional (7-items), emotional (6-items), and social/family (7-items) well-being. In addition, this instrument contains an 23-item brain cancer subscale (BCS) which assess symptoms commonly reported by [CONTACT_591754] [27]. Cancer-related fatigue will be assessed by [CONTACT_941] 13-item Fatigue Scale using the Functional Assessment of Cancer Therapy-Fatigue (FACIT-Fatigue) subscale, version 4 [67]. Cognitive problems will be assessed using version 3 of the Functional Assessment of Cancer Therapy-Cognition (FACT-Cog) subscale [68]. This includes subscales for perceived cognitive impairments (20 items), comments from others (4 items), perceived cognitive abilities (9 items), and impact of quality of life (4 items). Beck depression inventory (BDI) will be used to evaluate for underlying depressive symptoms. We will use the revised version (BDI-II) and the scores will range from 0 (no depression) to 63 (severe depression) [69]. The BDI contains 21 questions in regards to mood symptoms and is multiple-choice and self-reported. Exercise behavior will be assessed using the Godin Leisure questionnaire [70]. HRQoL PROs questionnaires will be obtained at screening, after standard RT and TMZ (within 2 to 4 weeks), and approximately every [ADDRESS_780241] of Care visit during adjuvant TMZ.  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 47 of 137 13.8.6 Cognitive Testing  Cognitive testing will include the performance on the following testing using a computerized battery CNS Vital Signs® [22] (Phase 1) and Brief Assessment of Cognition (BAC) through the NeuroCog app (Phase 2). The CNS Vital Signs® battery consists of seven tests that measure verbal and visual memory, finger tappi[INVESTIGATOR_007], symbol digit coding, the Stroop Test, a test of shifting attention, continuous performance test. Verbal memory test will assess verbal learning, memory for words, immediate recall, and delayed recall. Visual memory tests will assess visual learning, memory for geometric shapes, immediate recall, and delayed recall. Finger tappi[INVESTIGATOR_591701]. Symbol digit coding test will evaluate complex attention, visual-perceptual speed, and information processing speed. Stroop Test will assess executive function, simple and choice reaction time, speed-accuracy trade-off, information processing speed, and inhibition/disinhibition. Shifting attention test will assess executive function, reaction time, and information processing speed. Continuous performance test will assess sustained attention and choice reaction time. Normative data is available for this testing through CNS Vital Signs® and patients’ performance will be compared to this normative data. In Phase 2, the BAC battery of tests is implemented through an iPad based app called the BAC App (the vendor that provides this is called VeraSci, previously called NeuroCog) [22]. The table below shows a description of the BAC App Subtests. Examples are included in Appendix E.  The verbal responses provided during the tests conducted with the iPad will be audio recorded.   These audio recordings will be used by [CONTACT_591755].  The audio recordings will be stored and van be viewed later using VeraSci’s proprietary portal, which appropriate credentials are needed to access.  They will be retained for the period of time specified for all other study data or as required by [CONTACT_2371].    Cognitive testing with the BAC App will be obtained at screening (for the baseline assessment), after standard RT and TMZ (within 2 to 4 weeks), and approximately every [ADDRESS_780242] completion of treatment timepoint, cognitive testing should still be collected at those timepoints. Additional cognitive testing (HVLT-R, COWA, and TMT) will be performed at these selected times: baseline, standard of care visit before the start of the first cycle of adjuvant temozolomide, and standard of care visits that are 6 and 12 months from the completion of radiotherapy/chemotherapy. These tests will be performed by a trained neuropsychologist or delegate at the clinical center. The tests will include Hopkins Verbal Learning Test-Revised to assess learning, total recall, and memory [71], Trails Making Test Parts A and B to assess attention and executive function [72], and Controlled Oral Word Association Test to assess verbal fluency [73].  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 48 of 137 Table 5: Description of the BAC App Subtests. Traditional BAC App Battery. List of tests, the domains of cognition they assess, a description of the methodology for assessment and the total time for test administration. Domain BAC Subtest Summary Duration (mins) Verbal Memory & Learning Verbal Memory   Subject is presented with 15 words and asked to recall as many as possible. This procedure is repeated 5 times. Outcome measure: Number of words recalled  [ADDRESS_780243] is presented with auditory clusters of numbers (e.g. 9, 3, 6) of increasing length and asked to tell the rater the numbers in order from lowest to highest.  Outcome measure: Number of correct responses [ADDRESS_780244] is presented with tokens and asked to drag them to a center container as quickly as possible for 60 seconds.  Outcome measure: Number of tokens correctly dragged into the container  [ADDRESS_780245] is given 60 seconds to verbally generate as many words as possible in a given category. Outcome measure: Number of words generated [ADDRESS_780246] is given 60 seconds to verbally generate as many words as possible beginning with a given letter of the alphabet.  Outcome measure: Number of words generated  Speed of Processing Symbol Coding Subject is provided a key and asked to fill in the corresponding numbers beneath a series of symbols as quickly as possible within 90 seconds.  Outcome measure: Number of correct items  [ADDRESS_780247] is asked to give the minimum number of times the balls in one pi[INVESTIGATOR_591702]. Outcome measure: Number of correct responses 7  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 49 of 137 13.8.7 Hair Integrity and Hair Loss Subjective assessments of hair loss will be obtained by [CONTACT_591756] (baseline), after standard RT and TMZ finishes (within 2 to 4 weeks), and standard of care (SOC) clinic visit (approximately every 8 weeks) during adjuvant TMZ.   The photographs will be taken of the craniotomy scar (surgical incision site) and can be taken at any angle or background approximately 6-48 inches from the scalp. There will be no identifiers on the photographs. Up to 6 photographs may be taken at any one time point. Photographs will not include the subjects entire face (will not include eyes, nose, mouth). The photographs will be taken by [CONTACT_978] [INVESTIGATOR_591703], kept in a separate electronic research file or on paper. One photo per timepoint will also be uploaded to the sponsor electronic database.  Participation in these pi[INVESTIGATOR_591704]. Hair loss will be subjectively described and evaluated clinically by [CONTACT_591757]. If the patient is bald, the photos and descriptions may be omitted.   13.8.[ADDRESS_780248] of general demographic information (e.g., race, ethnicity, education, employment, smoking status). Demographic information should be collected at the time of screening.  Medical information will be abstracted from medical records and study questionnaires.  13.8.9 Bone Marrow Assessments  Bone marrow function will be assessed by [CONTACT_591758] (which includes platelet counts) as described in the table in Section 13 Screening and On-Study Tests and Procedures. 13.8.10 MRI Diffusion Tensor/Susceptibility Imaging MRI diffusion tensor/susceptibility imaging during Phase [ADDRESS_780249] agent injection as specified in the standardized brain tumor imaging protocol (BTIP, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588759/, Table 1).  T2 and FLAIR imaging should also be performed as specified in this publication.   For susceptibility images, images will be acquired using a multi-echo 3D gradient echo sequence.     For Siemens scanners, use the following parameters:   TE1 =min TR =60 ms flip angle = 12º FOV = 220x220 mm2 matrix size = 256x256, 2mm slice thickness with no gaps, parallel imaging acceleration factor 2.   For GE scanners, use the following parameters:  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 50 of 137  TE1 =min TR =45 ms flip angle = 12º FOV = 220x220 mm2 matrix size = 256x256, 2mm slice thickness with no gaps, parallel imaging acceleration factor 2.    Obtain maximum number of echoes (at least 9).  Sites should reconstruct and save both magnitude and unfiltered phase images from this sequence.  Diffusion tensor images will be acquired before contrast injection using a multi-channel head coil (at least 8-channels) and a standard single-shot EPI [INVESTIGATOR_591705] a parallel-imaging acceleration factor of 2. The parameters will be as follows: TE = 82 ms, TR = 8 s, FOV = 220x220 mm2, matrix size = 128x128, slice thickness = 2 mm without gap, b-value = 1000 s/mm2, 5 non-diffusion weighted images and 25 diffusion encoding directions. 75 slices will be acquired to cover the whole brain.   These images will be obtained three times during the study: on day -[ADDRESS_780250] RT and TMZ (within 2 to 4 weeks), and [ADDRESS_780251] RT and TMZ (within 2 to 4 weeks).   Images will be cleaned of identifiers (except for the date of the scan which is needed for analysis), encrypted and transferred to the Duke Imaging center for analysis.  Please see the sponsor provided Imaging Manual for specifics.   13.8.11 Drug Levels and Pharmacokinetic Assessment See Appendix B, Section 19.2.  In Phase 2, only 6 subjects enrolled in Arm A (at Duke) will have PK samples drawn.    
Protocol #: BMX-HGG-[ADDRESS_780252] or evaluation of study assessments, whether an AE or SAE has occurred. 14.1 Adverse Events An adverse event (AE) is any untoward medical occurrence in a study subject which does not necessarily have a causal relationship with this treatment. For this protocol, the definition of AE also includes worsening of any pre-existing medical condition. An AE can therefore be any unfavorable and unintended or worsening sign (including an abnormal laboratory finding), symptom, or disease that occurs in any subject enrolled in this clinical trial. It may or may not be related to use of the BMX-001. Abnormal laboratory findings without clinical significance (based on the Principal Investigator’s judgment) should not be recorded as AEs. But laboratory value changes that require therapy or adjustment in prior therapy are considered adverse events.  From the time the subject signs the informed consent form through 30 days after completion of the final BMX-001 treatment (for subjects in Arm A, this will be [ADDRESS_780253] chemo/RT for subjects in Arm B), all AEs must be recorded in the subject medical record and adverse events case report form.  AEs will be assessed according to the CTCAE version 4.03. If CTCAE grading does not exist for an AE, the severity of the AE will be graded as mild (1), moderate (2), severe (3), life-threatening (4), or fatal (5).  Attribution of AEs will be indicated as follows: - Definite: The AE is clearly related to the BMX-001 - Probably: The AE is likely related to the BMX-001 - Possible: The AE may be related to the BMX-001 - Unlikely: The AE is doubtfully related to the BMX-001 - Unrelated: The AE is clearly NOT related to the BMX-001 14.1.1 Reporting of AEs BioMimetix JV, LLC should be notified of all treatment-related adverse events on a regular basis (to be agreed upon by [CONTACT_591759], LLC).  14.2 Serious Adverse Events An AE is considered “serious” if in the opi[INVESTIGATOR_35412]: - Fatal - Life-threatening - Constitutes a congenital anomaly or birth defect - A medically significant condition (defined as an event that compromises subject safety or may require medical or surgical intervention to prevent one of the three outcomes above). - Requires inpatient hospi[INVESTIGATOR_1081] - Results in persistent or significant incapacity or substantial disruption to conduct normal life functions. 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 52 of 137 14.2.1 Reporting of SAEs Only adverse events that the Sponsor and/or Principal Investigator [INVESTIGATOR_591706], unanticipated, and related or possibly/probably (i.e., more likely than not) related to the research must be reported to the sponsor. Those adverse events will be submitted, according the following guidelines: • Report within [ADDRESS_780254]’s death that was unanticipated and more likely related to the research than unrelated; • Report within 5 business days of learning about any serious, unanticipated, and related or possibly/probably related adverse event; or other unanticipated problem or event that was more likely related to the research than unrelated. • Report within [ADDRESS_780255] report to the FDA, in an IND safety report, any suspected adverse reaction that is both serious and unexpected. Before submitting this report, the sponsor needs to ensure that the event meets all three of the definitions contained in the requirement:  • Suspected adverse reaction (i.e. there is a reasonable possibility that the drug caused the adverse event) • Serious  • Unexpected   If the adverse event does not meet all three of the definitions, it should not be submitted as an expedited IND safety report.  The Sponsor is required to report to the FDA all IND Safety reports in writing within 15 days (7 days for unexpected fatal or life-threatening suspected adverse reaction). The FDA Form 3500A can be found on the FDA website, www.fda.gov. All other adverse events will be reported to the FDA in the IND Annual Report.  In addition to the above mentioned reporting responsibilities, after discontinuation of the study, all SAEs considered to be drug related will be reported to BioMimetix JV, LLC, by [CONTACT_079]. 14.[ADDRESS_780256] (DSMB) The DSMB-Plus established for Phase 1 will be used for Phase 2 during the period that Duke Cancer Center is the only participating clinical center. When additional clinical centers are added to the Phase 2 study, the DSMB-Plus will be modified to become a DSMB-Plus which has oversight for all clinical centers.  This will involve approval of a new charter.    The sponsor and Principal Investigators are responsible for overseeing the safety and efficacy of the trial, executing the DSMB plan, and complying with all reporting requirements to local and federal authorities. Additional oversight will be carried out by [CONTACT_591760] 2.  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 53 of 137 An external DSMB-Plus will be utilized to monitor Phase 2 when this becomes a multi-center study. This DSMB will be organized to meet requirements of Western IRB, the institutional IRBs, and the NCI. We anticipate a charter with a minimum of 3 members, which may include: a radiation oncologist with experience in high grade glioma, a medical oncologist with expertise in high grade glioma, a biostatistician, and/or an ethicist or patient advocate. The responsibilities of the DSMB will be to review safety of study procedures, to maintain study integrity, to review adverse events and to review efficacy of the outcome data. The DSMB will meet either face to face or by [CONTACT_591761]-annually and on an ad hoc basis as indicated by [INVESTIGATOR_60711]. Minutes will be kept of both open and closed meetings of the DSMB. At the end of the study, all minutes taken will be available to the clinical trial principal investigators, the NCI, and BioMimetix JV, LLC.  The DSMB’s responsibilities will include evaluation of treatment outcome for evidence of tumor protection by [CONTACT_5257]. The DSMB will have authority to recommend closure of the clinical trial for either efficacy or futility.   
Protocol #: BMX-HGG-[ADDRESS_780257] one visit approximately every 10 weeks, while the study is enrolling and subjects are receiving treatment.   Additional monitoring may be prompted by [CONTACT_12637], unexpected frequency of serious and/or unexpected toxicities, or other concerns and may be initiated upon request of the clinical center institution, the Sponsor, the Clinical Center Principal Investigator, or the IRB. All study documents must be made available upon request to the clinical trial monitor and other authorized regulatory authorities, including but not limited to the National Institute of Health, National Cancer Institute, and the FDA. Every reasonable effort will be made to maintain confidentiality during study monitoring. 15.1.1 DSMB-Plus Per the recommendation of the Duke School of Medicine Research Integrity Office (RIO), a data safety monitoring board DSMB-Plus has been formed and a charter has been established for periodic review and assessment of data and outcomes to assure continuing safety of research participants in this trial. The committee will participate in decisions regarding reports or publications to ensure there is no bias as a result of conflict of interest questions. Because of Duke University’s potential for conflict of interest with BMX-001, the Duke RIO has recommended use of a DSMB-Plus for review of the study for bias in the protocol design, performance of the study, and assessment of endpoints and ongoing periodic assessment of adverse events and study conduct.  Members of the DSMB-Plus will be approved by [CONTACT_591762] a DSMB-Plus charter established. For Phase [ADDRESS_780258] on a cohort (dose level) has reached [ADDRESS_780259] dose of BMX-001. DSMB-Plus review will be prior to each dose escalation.   In Phase 2, the DSMB-Plus will meet twice a year.  The DSMB-Plus will review safety and data reports which will be provided by [CONTACT_591763].  Review of data can be via WEBEX or teleconference. Copi[INVESTIGATOR_591707]-Plus meeting minutes will be provided to RIO office ([CONTACT_591786]) within [ADDRESS_780260], or reporting of the research related to BMX-001.   
Protocol #: BMX-HGG-[ADDRESS_780261] of the study should be kept by [CONTACT_326160] [INVESTIGATOR_591708]. 15.3.3 Coding All medical terms will be coded using CTCAE v.4.03, which has been harmonized to MedDRA (Medical Dictionary for Regulatory Activities) coding.  15.3.4 Study Closure Following completion of the study, the Clinical Center Principal Investigator [INVESTIGATOR_12599]: • Data clarification and/or resolution of queries • Accounting, reconciliation, and destruction/return of used and unused study drugs • Review of site study records for completeness • Shipment of all remaining laboratory samples to the designated laboratories   
Protocol #: BMX-HGG-[ADDRESS_780262] be approved by [CONTACT_12641]. 16.1 Analysis Sets  MTD Analysis Set: Patients who complete concurrent chemoradiation with scheduled treatments with BMX-001 or terminate treatment during that period of time due to DLT will be considered evaluable and included in the analysis of MTD.   Adverse Experience Analysis Set: All patients who receive BMX-001 will be included in any overall summary of adverse experienced.  Survival Analysis Data Set: All patients who receive BMX-001 will be included in analyses of survival and progression-free survival.  PRO / Cognition Analysis Set: All patients who receive BMX-001 and provide a follow-up assessment will be included in statistical analyses of HRQoL and cognition.  The MTD Analysis dataset as described above is applicable to the Phase 1 portion of this study; whereas, the other datasets are applicable to both the Phase 1 and Phase 2 portions of this study.  16.2 Patient Demographics and Other Baseline Characteristics For each phase of this study, the clinical and socio-demographic characteristics of all patients treated will be summarized using descriptive statistics (e.g. means/standard deviations, percentiles, frequencies). Patient characteristics within patient subgroups defined by [CONTACT_591764] 1 portion of this protocol. Within the Phase 2 portion, patient characteristics will be summarized by [CONTACT_48977]. 16.3 Treatments Within the Phase 1 portion of this study, the number of patients treated at each dose level will be summarized.  Within the Phase 2 portion of this study, a CONSORT diagram will be generated that displays the number of patients treated within each treatment arm, as well as the number of cycles of adjuvant treatment received. 16.4 Phase 1 Dose Escalation 16.4.1 Primary Objective The primary objective of this Phase 1 study is to determine the maximum tolerated dose (MTD) of BMX-[ADDRESS_780263] radiotherapy and daily TMZ among patients with newly diagnosed HGG. Four dose levels are planned and are described in Section 9.1.1.  [IP_ADDRESS] Variable Based upon all available data and the CRM model described in Section [IP_ADDRESS], the MTD will be the dose with the estimated DLT rate closest to the target DLT rate of 0.25. 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 57 of 137 [IP_ADDRESS] CRM Design Considerations Though 3+[ADDRESS_780264] 3+3 design. Specifically, the 3+3 design suffers from the problem of “memory loss” that occurs as dose is escalated. In addition, the 3+[ADDRESS_780265] a statistical justification, and does not involve an explicit target DLT rate [74].   A two-stage CRM design will be used to determine the MTD of BMX-[ADDRESS_780266] stage involves dose escalation in successive patients until an initial dose-limiting toxicity (DLT) is observed. Within the second stage, all accumulated data will be used within the context of a one-parameter logistic model to determine the appropriate dose for each subsequent patient. Maximum likelihood estimation will be used. This modeling process will determine the dose with a DLT rate closest to the target DLT rate of 0.25. Cohorts of 3 patients will be accrued to this study within both stages of the trial.   The remaining portion of this section provides information about the development of the CRM model that is to be used specifically for this study. R software developed by [CONTACT_591765] [75] aided in its development.  MTD: No dose-limiting toxicities (DLTs) were observed in monkey toxicity studies for BMX-[ADDRESS_780267] DLTs to occur within the range of doses that will be used in this Phase 1 study.  One-stage versus two-stage CRM: With no expectation that DLTs will be observed among the doses that will be investigated in this study, the use of a one-parameter CRM model is inappropriate as such a model assumes that the initial patient is treated at the prior or expected MTD. Rather, a two-stage CRM with dose escalation restriction will be used. The first stage involves a predetermined dose escalation scheme that starts at dose level [ADDRESS_780268] to a dose escalation restriction. That restriction requires that the dose for the next patient cannot be more than one level higher than that of the current patient.  Target DLT rate (θ): CRM designs used for oncology therapeutic trials are often designed with a target DLT rate (θ) between 0.[ADDRESS_780269] a target DLT rate of 0.25.  Sample size: Cheung [75] suggests that the fixed sample size used in one-stage CRM designs be constrained so that  !"#	(#	'()*	+*,*+)"-)-  >  /0123*4	560	714*  If this study was a one-stage study, the implication of this constraint is that N > 14. For the two-stage design, Cheung [75] recommends that the number of observations reserved for the highest dose level in case of no toxicity should be greater than 1.5/target DLT rate, or 6 for this study. The simulations described below consider a fixed sample size ranging between 16 and 20 patients.  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 58 of 137 Functional form of model: The logistic and empi[INVESTIGATOR_591709]. The one-parameter logistic model has the following form where β is an unknown parameter to be estimated:   Probability of DLT = 89:(	#;89:(<)'()*	)/;89:(	#;89:(<)'()*	)  The one-parameter model has the following functional form:  Probability of DLT = doseexp(β)  Simulations reported below examine the impact of functional form (logistic and empi[INVESTIGATOR_29121]) on model inference.  Initial guess of toxicity probability: Within the second stage of the CRM model, there is a need to specify a set of initial guesses for the dose-specific probability of DLT. Referred to as the skeleton of the CRM, this initial guess at toxicity probability is increasing with dose. Even with good clinical guesses for the skeleton, the resulting CRM model may fail regularity conditions required for the study to have good operating characteristics. As an alternative, an initial toxicity probability distribution can be generated so that the CRM is δ-sensitive. A δ-sensitive CRM will eventually select a dose as the MTD with toxicity falling between θ±δ [74].  The GETPRIOR function available within the R-package DFCRM was used to estimate the skeleton assuming δ was 0.03, 0.05, 0.07 [74,76,77]. Though we expect that DLT will not be encountered at any dose level, we will assume that the prior MTD is dose level 5. Tabulated below are the initial guesses generated by [CONTACT_591766] (logistic or empi[INVESTIGATOR_29121]).   Initial Guess of Toxicity Probability with Empi[INVESTIGATOR_591710] (δ) Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 0.03 0.097 0.141 0.192 0.250 0.05 0.036 0.084 0.157 0.250 0.07 0.009 0.043 0.124 0.250    Initial Guess of Toxicity Probability with Logistic Model Delta (δ) Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 0.03 0.101 0.143 0.193 0.250 0.05 0.044 0.089 0.158 0.250 0.07 0.016 0.051 0.127 0.250  Initial design: The GETINIT function within the R-package DFCRM was used to identify compatible and coherent initial designs given the identified initial guesses of toxicity probability and the model’s functional form (logistic or empi[INVESTIGATOR_29121]) [74,75]. The algorithm started the search for an initial design with the most aggressive initial design that started the trial at the second highest dose. More conservative designs were subsequently tested for compatibility if the current design compatible.   Compatible designs exist that involve treating cohorts of [ADDRESS_780270] of dose on cognition. Hence, an initial design with cohorts of 3 patients will be used to garner additional information about the cognitive effects of BMX-001 treatment. 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 59 of 137  Cohort size during the second stage: With an accrual rate of approximately 3 patients per month, the observation period for the determination of DLT is 4 weeks. Cohort sizes of 3 will be considered for the second stage.   Study Simulations: The performance of the two-stage design CRM design was examined under a variety of conditions, including functional form [logistic vs empi[INVESTIGATOR_29121]], initial guess of DLT toxicity probabilities, cohort size, overall sample size [17,19,21]), and various true underlying toxicity probability profiles using the CRMSIM function within the R-package DFCRM [74,75,78]. Results based upon [ADDRESS_780271] the following: • The majority of simulations identify the correct MTD dose, or a contiguous dose. • The probability of selecting a dose as the MTD is comparable with the two different functional forms. • When the MTD is at a higher dose, the probability of declaring that dose as the MTD is greatest when the initial guess of toxicity probability assumes δ=0.03. • Increasing the maximum number of subjects from [ADDRESS_780272] of this study: • Logistic functional form • Initial guess of toxicity probability that assumes δ=0.03, i.e. (0.101, 0.143, 0.193, 0.250) • The maximum number of patients evaluable for the determination of MTD that will be enrolled is 18. • Cohorts of 3 patients will be accrued to this study within both stages of the trial.  [IP_ADDRESS] Implementation of Phase 1 Study Initial Design / Stage 1: As described above, this Phase [ADDRESS_780273] stage, cohorts of 3 patients will be treated starting with dose level #1. Once [ADDRESS_780274] been undergone treatment without experiencing DLT after a monitoring period of four weeks after completion of all doses of BMX-001, the dose of the subsequent group of 3 patients will be escalated. This process will continue until a patient experiences a DLT.  Model-Based Escalation / Stage 2: Within stage 2, patients will be accrued to the study in cohorts of 3 patients. Whenever the toxicity outcomes associated with patients within a cohort are known, the one-parameter logistic model will be re-estimated by [CONTACT_1758]’s statistical team using all available data. Based upon this re-estimated model, the dose level that results in a DLT rate nearest to the target DLT rate will be determined, and used to treat the next patient subject to a dose escalation restriction. That restriction requires that the dose for the next patient cannot be more than one level higher than that of the current patient.   Study Termination: A maximum of [ADDRESS_780275] been treated at a dose level without any indication that the dose should be escalated or de-escalated [74]. [IP_ADDRESS] Secondary Objectives of Phase 1 Study Adverse events will be tabulated in a different manner for the manuscript summarizing the results of this study, annual reports for the Safety Oversight Committee, and the final report included within ClinicalTrials.gov.  
Protocol #: BMX-HGG-[ADDRESS_780276] of care treatment consisting of temozolomide and RT. Analyses will be sub-divided in terms of WHO grade and histological subtype.   Kaplan-Meier methods will be used to graphically describe the distribution of overall survival (OS) and progression-free survival. OS is defined as the time interval between initiation of protocol treatment and death, with overall survival censored at last follow-up if the patient remained alive. PFS is defined as the time between initiation of protocol treatment and disease progression or death. If the patient remains alive without disease progression, then PFS will be censored at last follow-up. Median OS and PFS, as well as 6- and 12-month estimates of OS and PFS will be estimated from the Kaplan-Meier curve. Because OS and PFS can differ in HGG based on grade (WHO grade III vs IV) and histological subtype (e.g. anaplastic oligodendroglioma vs. anaplastic astrocytoma), analyses will be sub-divided in terms of WHO grade and histological subtype.  The radiographic response rate will be calculated as the proportion of patients with a complete or partial response for all patients and within subgroup of patients defined by [CONTACT_479]. Exact binomial confidence intervals will be computed.  Pharmacokinetics will be done as described in Appendix B (Section 19.2). [IP_ADDRESS] Exploratory Objectives of Phase 1 Study The mean change between baseline and each follow-up assessment for HRQoL will be computed as was computed for cognitive function outcome variables. Analyses will be sub-divided in terms of WHO grade and histological subtype. Hair loss is a descriptive measure and will be defined and analyzed using pi[INVESTIGATOR_499].  [IP_ADDRESS] Interim Analysis of Phase 1 Study See Sections [IP_ADDRESS] and [IP_ADDRESS]. [IP_ADDRESS] Sample Size Calculation See Section [IP_ADDRESS]. 16.[ADDRESS_780277] of care (SOC) treatment consisting of daily TMZ and RT.  [IP_ADDRESS] Variable The study’s primary endpoint is OS as defined by [CONTACT_591767], or the last follow-up if the patient remains alive. 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 61 of 137 [IP_ADDRESS] Statistical Hypothesis, Model, and Method of Analysis  As stated in section 7.6, this study will assess the hypothesis that BMX-001, when added to standard RT and TMZ, will sensitize the malignancy and result in enhanced patient survival.  All randomized patients will be included in the analysis of survival and included in their assigned treatment arm regardless of compliance. This approach to analysis is consistent with an intent-to-treat analysis approach.  Kaplan-Meier methods will be used to graphically describe the distribution of overall survival (OS) among patients within the BMX group and within the control group. Median OS and PFS, as well as 6- and 12-month estimates of OS and PFS will be estimated from the Kaplan-Meier curve. A logrank test will compare arms with respect to the survival outcome.  Because OS can differ in HGG based on grade (WHO grade III vs IV) and histological subtype (e.g. anaplastic oligodendroglioma vs. anaplastic astrocytoma), the survival of patient subgroups of patients defined by [CONTACT_591768]. 16.5.[ADDRESS_780278] of BMX-001 on cognition, thrombocytopenia, adverse events, progression free-survival, radiographic response, and pharmacokinetics. [IP_ADDRESS] Secondary Objective #1 for Phase 2: Cognition The key secondary objective includes an evaluation and comparison of cognition among patients newly diagnosed with HGG and whether the addition of BMX-[ADDRESS_780279] to the pattern of cognitive change observed over time. Initially a repeated measures analysis will be conducted. However, a significant amount of the follow-up cognitive assessments may be missing due to health decline, disease progression, and death. The patterns of “drop-out” in the two treatment arms may also differ. To address these problems, additional analyses will be conducted. These analyses may focus on only assessments with relative complete data, or may consider alternative analytic methods such as pattern mixture models. [IP_ADDRESS] Secondary Objective #2 for Phase 2: Thrombocytopenia The proportion of patients who experience grade [ADDRESS_780280] will be conducted to compare the prevalence of such thrombocytopenia observed in patients with and without BMX-001.  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 62 of 137 In addition, the longitudinal patterns of platelet count over time will be explored in mixed linear models that account for within patient correlation. These longitudinal patterns will focus on the time period during BMX-001 treatment administration that continues for 2 weeks after radiation treatment is completed. [IP_ADDRESS] Secondary Objective #3 for Phase 2: Adverse Events The phase 2 portion of this study has two adverse event endpoints: (1) The proportion of patients who experience any grade 3 or 4 adverse event during radiation and temozolomide treatment, and (2) The proportion of patients who experience a grade 3 or 4 adverse event that is definitely, possibly, or probably related to BMX-001 treatment during this same period. Adverse events occurring between baseline through 2 weeks after discontinuation of radiation will be the focus of these analyses.  Adverse Event Monitoring and Tabulations: Adverse events will be tabulated in a different manner for semi-annual reports to the DSMB-Plus / DSMB, the manuscript summarizing the results of this study, and the final report included within ClinicalTrials.gov.   DSMB-Plus / DSMB Monitoring: Two tabulations of adverse events occurring during concurrent chemoradiation will be generated for DSMB-Plus / DSMB review including one that includes all toxicities regardless of attribution, and another that includes only toxicities that are possibly, probably, and definitely related to BMX-[ADDRESS_780281] the number of patients who experience each type of toxicity regardless of grade or attribution.  [IP_ADDRESS] Secondary Objective #4 for Phase 2: Progression-Free Survival Progression-Free Survival (PFS) is defined as the time between initiation of protocol treatment and disease progression or death. If the patient remains alive without disease progression, then PFS will be censored at last follow-up. Analyses similar to those described for OS will be generated for PFS.  [IP_ADDRESS] Secondary Objective #5 for Phase 2: Radiographic Response Radiographic response will be determined by [CONTACT_591769]. The radiographic response rate is defined as the proportion of patients of with a complete or partial response. The response rate within each arm will be calculated, and compared using an exact chi-square test. Additional analyses will describe the response rate within patient subgroups defined by [INVESTIGATOR_216], WHO grade and histological subtype. Exact binomial confidence intervals will be generated for each response rate estimate. [IP_ADDRESS] Secondary Objective #6 for Phase 2: Pharmacokinetics Pharmacokinetics will be done as described in Appendix B (Section 19.2).   16.5.3 Exploratory Objectives for Phase 2 Three exploratory objectives will be pursued within this protocol. This includes an assessment of health-related quality of life, a description of hair loss, and an examination of changes in white matter integrity.  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 63 of 137 Many of the proposed exploratory analyses assume methods for normally distributed data are appropriate. If underlying assumptions for planned analyses are violated, plans will be modified. Alternative analytic methods may also be considered to assess the robustness of inferences.  Additional statistical analyses may be conducted besides those described in this protocol. These additional analyses may be motivated by [CONTACT_591770], or they may be suggested by [CONTACT_591771]-specified in this protocol. [IP_ADDRESS] Exploratory Objective #1 for Phase 2: Health-Related Quality of Life Methods described in section 13.8.5 will be used to analyze HRQoL data. Given that numerous endpoints will be examined in these exploratory analyses, adjustments for multiple comparisons (e.g. false discovery rate methods or Bonferroni) may be considered. [IP_ADDRESS] Exploratory Objective #2 for Phase 2: Hair Loss Qualitative assessments of hair loss depi[INVESTIGATOR_591711]. Changes observed in Arm A will be compared to those observed in Arm B. [IP_ADDRESS] Exploratory Objective #3 for Phase 2: White Matter Integrity The mean change between baseline and each follow-up assessment for white matter integrity, as measured by [CONTACT_591772]/susceptibility imaging will be computed. Assuming normality, analysis of variance or a repeated measures analysis may be used to compare change in Arms A and B. Additional analyses will be sub-divided in terms of WHO grade and histological subtype.  16.5.4 Interim Analysis for Phase 2 Interim analyses using an O’Brien-Fleming boundary will be conducted with the goal of terminating accrual early to accept or reject the null hypothesis of no difference in survival. Given the inflated type I error rate for this Phase 2 study, early termination will only be considered if it appears that the addition of BMX-001 treatment to radiation and temozolomide is decreasing survival. The interim analysis will be conducted to determine whether the addition of BMX-001 is possibly detrimental to the survival of patients.   Interim analyses for the primary endpoint (survival) will be conducted annually beginning June 2021. The decision rule for accrual suspension will be defined by [CONTACT_941] O’Brien-Fleming spending function and is dependent upon the number of deaths that will have been reported by [CONTACT_591773]. If the boundary is crossed, accrual will be suspended while all other data (e.g. cognitive function data) is reviewed to determine whether accrual should be permanently terminated.  Though not part of the formal interim decision-making described above, additional interim analyses of secondary and exploratory outcomes will be conducted for multiple purposes, including assessment of data completeness and program planning.  Currently, the planned time of these analyses is as follows:  Date Planned Analysis June 2020 Among the initial 80 patients treated, changes in platelet counts  during radiation and temozolomide treatment and ending 2 weeks after termination of radiation will be examined.  The consistency of these counts with AE reports will also be assessed. December 2020 Among the initial 80 patients treated on the study, changes in neurocognition and quality of life PROs through week 24 will be examined.  Patterns of data missingness will be assessed, including reasons for missed assessments. June 2021 Among the initial 80 patients treated on the study, changes in neurocognition and quality of life PROs through week 52 will be examined.  Patterns of data missingness will be assessed, including reasons for missed assessments. The 
Protocol #: BMX-HGG-[ADDRESS_780282] of this interim analysis may be dependent upon any issues occurring in the December 2020 analysis.  16.5.5 Sample Size Calculation for Phase 2 Though the primary outcome of this study as currently design is overall survival, an important secondary outcome is the change in cognition. Power calculations will be presented for both outcomes. [IP_ADDRESS] Power of Survival Comparisons The primary goal of the Phase [ADDRESS_780283] of care treatment consisting of temozolomide and radiation on the survival of patients newly diagnosed with grade III or IV glioma. A permuted block randomization stratified by [CONTACT_591774] (grade III / IV) and institution will be used to assign patients to treatment with or without BMX-001.  With standard treatment, the median survival of Grade IV patients is 14.6 months, and the median survival of Grade III is approximately 36 months. Given that we anticipate that approximately 10% of patients to be Grade III, we estimate that the overall median survival with standard treatment to be roughly 16.[ADDRESS_780284] the primary statistical hypothesis while maintaining reasonably high power [80-82].   The power of a statistical comparison of survival is a function of the number of deaths observed. In order that a 1-tailed logrank test conducted at the 0.[ADDRESS_780285] 90% power to detect a hazard ratio of 0.63, [ADDRESS_780286] ratio represents an increase in median survival from 16.7 to 26.5 months.   With an accrual goal of 160 patients and an expected randomization rate of approximately 6 patients per month, we anticipate that accrual will be completed within approximately 27 months. It is estimated that approximately 10 months after accrual completion are needed to observe approximately 84 deaths among randomized patients.  [IP_ADDRESS] Cognition as Outcome Changes in cognition is an important issue with treatment of HGG patients with radiation. As such, an important secondary objective of this study is to determine whether treatment with BMX-[ADDRESS_780287] to change in cognitive function between baseline and week 24. Studies recently conducted at Duke 
Protocol #: BMX-HGG-[ADDRESS_780288] conducted at the 0.05 level of significance (two-tailed) will have 80% power to detect a difference of 15.5. [IP_ADDRESS] Thrombocytopenia as Outcome Platelet counts will be obtained during radiation and temozolomide treatment and ending 2 weeks after termination of radiation. The percentage of patients within each treatment group that experience grade 3 or 4 thrombocytopenia will be estimated. Gerber [1] reports that 15% of patients who receive standard radiation and temozolomide experience grade 3 or 4 thrombocytopenia. With 80 patients per arm, there is 80% power with a one-tailed chi-square test (α=0.05) to detect a reduction in grade 3 or 4 thrombocytopenia from 15% in Arm B (without BMX-001) to 4% in Arm A (with BMX-001).  17 ADMINISTRATIVE AND ETHICAL CONSIDERATIONS 17.1 Regulatory and Ethical Compliance This protocol was designed and will be conducted and reported in accordance with the International Conference on Harmonization (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice, the Declaration of Helsinki, and applicable federal, state, and local regulations. 17.2 Institutional IRBs and Research Committees It is expected that the protocol, informed consent form, advertising material (if applicable), and additional protocol-related documents must be submitted to the local clinical center Institutional Review Board’s (IRB) and internal committees in addition to the external Central IRB (WIRB for this study) for review. The study will first be submitted to WIRB by [CONTACT_591775], after WIRB approval, to the local IRBs, if required. The study may be initiated only after the Principal Investigator [INVESTIGATOR_591712].  The Principal Investigator [INVESTIGATOR_591713], continuing review, as well as informing any appropriate committee about protocol amendments that potentially affect research design or data analysis (i.e. amendments affecting subject population, inclusion/exclusion criteria, agent administration, statistical analysis, etc.).  The sponsor will handle study level submissions to the Central IRB, and the site will be responsible for handling site-specific submissions to the Central IRB. 17.[ADDRESS_780289] the Principal investigator [INVESTIGATOR_591714], and will be given as much time as needed to make an informed decision about participation in the study. 
Protocol #: BMX-HGG-[ADDRESS_780290] or a legally acceptable representative. The original informed consent form (including any updated consent (re-consent) documents) will be stored with the source documents, and a copy of the informed consent form will be provided to the subject. The Principal Investigator [INVESTIGATOR_591715]/her primary care physician about participation in the study. If the subject agrees to such notification, the Principal Investigator [INVESTIGATOR_12606]’s primary care physician about the subject’s participation in the clinical study. 17.[ADDRESS_780291]’s data will be maintained.   To protect privacy, every reasonable effort will be made to prevent undue access to subjects during the course of the study. Prospective participants will be consented in an exam room where it is just the research staff, the patient and his family, if desired. For all future visits, interactions with research staff (study doctor and study coordinators) regarding research activities will take place in a private room. All research related interactions with the participant will be conducted by [CONTACT_35430].  To protect confidentiality, subject files in paper format will be stored in secure cabinets under lock and key accessible only by [CONTACT_16133]. Subjects will be identified only by a unique study number and subject initials. Electronic records of subject data will be maintained using a dedicated compliant database, which is housed in an encrypted and password-protected file on a secure network drive. Access to electronic databases (without edit rights) will be limited to the Principal Investigator, the study coordinator, and the statistical team. The only personnel with both access and edit rights to the electronic databases are the data management team, including the clinical trials manager.   For the diffusion tensor images, information that would directly identify the patient will be removed from the DICOM image datasets to produce a limited imaging dataset (for the purposes of this scan, a limited dataset has the [ADDRESS_780292] identifying information removed from the DICOM header, but may include information about the date/time of imaging and the imaging location).  The limited imaging dataset will then be transferred to Duke University for review and analysis.  The process of cleaning (removing patient identifiers from the images) and transferring the images is done by [CONTACT_591776].  The sponsor has provided an Imaging Manual for specific instructions on this process.    The results of the BAC App tests conducted on the iPad and the audio recordings included with them will be stored on a secure cloud based server maintained by [CONTACT_456]’s representative (VeraSci).  The electronic files, including the audio files, will be retained for the period of time specified for all other study data or as required by [CONTACT_2371].  Upon completion of the study, research records will be archived and handled per institutional policy. Subject names or identifiers will not be used in reports, presentations at scientific meetings, or publications in scientific journals. 17.5 Data and Safety Monitoring Data and Safety Monitoring will be performed in accordance with the Data and Safety Monitoring Plan. For a more detailed description of the DSMP for this protocol, refer to refer to the Safety Monitoring and Reporting section and the Quality Control and Quality Assurance section.  
Protocol #: BMX-HGG-[ADDRESS_780293] inform the Sponsor and the IRB and all other applicable regulatory agencies of such action immediately. 17.7 Records Retention The Principal Investigator [INVESTIGATOR_12608]-related records for the longer of a period of: - at least two years after the date on which a New Drug Application is approved by [CONTACT_1622], if an IND is involved - at least two years after formal withdrawal of the IND associated with this protocol, if an IND is involved - at least six years after study completion (Duke policy) or longer if required by [CONTACT_591777] 17.[ADDRESS_780294] appointments, publicly-traded or privately-held equities, stock options, intellectual property, and gifts.    
Protocol #: BMX-HGG-[ADDRESS_780295] of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 2007 Jan; 9(1):47-52. PMID: 17108062, PMC1828105. 2. Ross, A.D., et al., Hemodynamic effects of metalloporphyrin catalytic antioxidants: structure-activity relationships and species specificity. Free Radic Biol Med, 2002. 33(12): p. 1657-69. 3. Ohgaki, H., Epi[INVESTIGATOR_591716]. Methods Mol Biol, 2009. 472: p. 323-42. 4. Ross, G.M., Induction of cell death by [CONTACT_114658]. Endocr Relat Cancer, 1999. 6(1): p. 41-4. 5. Greene-Schloesser, D., et al., Radiation-induced brain injury: A review. Front Oncol, 2012. 2: p. 73. 6. Tofilon, P.J. and J.R. Fike, The radioresponse of the central nervous system: a dynamic process. Radiat Res, 2000. 153(4): p. 357-70. 7. Crossen, J.R., et al., Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol, 1994. 12(3): p. 627-42. 8. Giovagnoli, A.R. and A. Boiardi, Cognitive impairment and quality of life in long-term survivors of malignant brain tumors. Ital J Neurol Sci, 1994. 15(9): p. 481-8. 9. Klein, M., et al., Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet, 2002. 360(9343): p. 1361-8. 10. Meyers, C.A. and P.D. Brown, Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol, 2006. 24(8): p. 1305-9. 11. Osoba, D., et al., Effect of neurological dysfunction on health-related quality of life in patients with high-grade glioma. J Neurooncol, 1997. 34(3): p. 263-78. 12. Meyers, C.A., et al., Cognitive function as a predictor of survival in patients with recurrent malignant glioma. J Clin Oncol, 2000. 18(3): p. 646-50. 13. Klein, M., et al., Neurobehavioral status and health-related quality of life in newly diagnosed high-grade glioma patients. J Clin Oncol, 2001. 19(20): p. 4037-47. 14. Gilbert, M., T. Armstrong, and C. Meyers, Issues in assessing and interpreting quality of life in patients with malignant glioma. Semin Oncol, 2000. 27([ADDRESS_780296] 6): p. 20-6. 15. Liu, R., et al., Quality of life in adults with brain tumors: current knowledge and future directions. Neuro Oncol, 2009. 11(3): p. 330-9. 16. Budrukkar, A., et al., Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. J Neurooncol, 2009. 95(3): p. 413-9. 17. Brown, P.D., et al., Prospective study of quality of life in adults with newly diagnosed high-grade gliomas. J Neurooncol, 2006. 76(3): p. 283-91. 18. Taylor, B.V., et al., Effects of radiation and chemotherapy on cognitive function in patients with high-grade glioma. J Clin Oncol, 1998. 16(6): p. 2195-201. 19. Gregor, A., et al., Neuropsychometric evaluation of long-term survivors of adult brain tumours: relationship with tumour and treatment parameters. Radiother Oncol, 1996. 41(1): p. 55-9. 20. Jones, L.W., et al., Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testing. J Neurooncol, 2009. 94(1): p. 79-85. 21. Peters, K., et al. Neurocognitive dysfunction in newly diagnosed high-grade glioma patients: utilization of standardized computerized neurocognitive testing. in Society for Neuro-Oncology. 2013. San Francisco, CA. 22. Gualtieri, C.T. and L.G. Johnson, Reliability and validity of a computerized neurocognitive test battery, CNS Vital Signs. Arch Clin Neuropsychol, 2006. 21(7): p. 623-43. 23. Peters, K.B., et al. Long-term survivorship in primary glioblastoma: a focus on quality of life. in Society for Neuro-Oncology. 2012. Washington, DC. 24. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004;68(2-3):283-97. doi: 10.1016/j.schres.2003.09.011. PubMed PMID: 15099610. 25. Keefe RS, Harvey PD, Goldberg TE, Gold JM, Walker TM, Kennel C, et al. Norms and standardization of the Brief Assessment of Cognition in Schizophrenia (BACS). Schizophr Res. 2008;102(1-3):108-15. doi: 10.1016/j.schres.2008.03.024. PubMed PMID: 18495435. 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 69 of 137 26. Atkins AS, Tseng T, Vaughan A, Twamley EW, Harvey P, Patterson T, et al. Validation of the tablet-administered Brief Assessment of Cognition (BAC App). Schizophr Res. 2017;181:100-6. doi: 10.1016/j.schres.2016.10.010. PubMed PMID: 27771201. 27. Weitzner, M.A., et al., The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer, 1995. 75(5): p. 1151-61. 28. Chawla, S., et al., Radiation Injury to the Normal Brain Measured by 3D-Echo-Planar Spectroscopic Imaging and Diffusion Tensor Imaging: Initial Experience. J Neuroimaging, 2013. 29. Haris, M., et al., Serial diffusion tensor imaging to characterize radiation-induced changes in normal-appearing white matter following radiotherapy in patients with adult low-grade gliomas. Radiat Med, 2008. 26(3): p. 140-50. 30. Xu, J.L., et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging. Neuroradiology, 2010. 52(12): p. 1193-9. 31. Hope, T.R., et al., Serial diffusion tensor imaging for early detection of radiation-induced injuries to normal-appearing white matter in high-grade glioma patients. J Magn Reson Imaging, 2014. 32. Nagesh, V., et al., Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys, 2008. 70(4): p. 1002-10. 33. Ravn, S., et al., Differences in supratentorial white matter diffusion after radiotherapy--new biomarker of normal brain tissue damage? Acta Oncol, 2013. 52(7): p. 1314-9. 34. Chapman, C.H., et al., Diffusion tensor imaging of normal-appearing white matter as biomarker for radiation-induced late delayed cognitive decline. Int J Radiat Oncol Biol Phys, 2012. 82(5): p. 2033-40. 35. Butler, J.M., Jr., et al., A phase III, double-blind, placebo-controlled prospective randomized clinical trial of d-threo-methylphenidate HCl in brain tumor patients receiving radiation therapy. Int J Radiat Oncol Biol Phys, 2007. 69(5): p. 1496-501. 36. Kaleita, T.A., et al. Pi[INVESTIGATOR_280043]. in American Society of Clinical Oncology. 2006. Atlanta, GA: Journal of Clinical Oncology. 37. Shaw, E.G., et al., Phase II study of donepezil in irradiated brain tumor patients: effect on cognitive function, mood, and quality of life. J Clin Oncol, 2006. 24(9): p. 1415-20. 38. Zhao, W. and M.E. Robbins, Inflammation and chronic oxidative stress in radiation-induced late normal tissue injury: therapeutic implications. Curr Med Chem, 2009. 16(2): p. 130-43. 39. Navarro, J., et al., Blood glutathione as an index of radiation-induced oxidative stress in mice and humans. Free Radic Biol Med, 1997. 22(7): p. 1203-9. 40. Moeller, B.J., et al., Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell, 2004. 5(5): p. 429-41. 41. Moulder, J.E. and E.P. Cohen, Future strategies for mitigation and treatment of chronic radiation-induced normal tissue injury. Semin Radiat Oncol, 2007. 17(2): p. 141-8. 42. Stone, H.B., et al., Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003. Radiat Res, 2004. 162(6): p. 711-28. 43. Takahashi, I., et al., Clinical study of the radioprotective effects of Amifostine (YM-[ZIP_CODE], WR-2721) on chronic radiation injury. Int J Radiat Oncol Biol Phys, 1986. 12(6): p. 935-8. 44. Tannehill, S.P. and M.P. Mehta, Amifostine and radiation therapy: past, present, and future. Semin Oncol, 1996. 23([ADDRESS_780297] 8): p. 69-77. 45. Batinic-Haberle, I., et al., Diverse functions of cationic Mn(III) N-substituted pyridylporphyrins, recognized as SOD mimics. Free Radic Biol Med, 2011. 51(5): p. 1035-53. 46. Batinic-Haberle, I., et al., SOD therapeutics: latest insights into their structure-activity relationships and impact on the cellular redox-based signaling pathways. Antioxid Redox Signal, 2014. 20(15): p. 2372-415. 47. Batinic-Haberle, I., et al., Mechanistic considerations of the therapeutic effects of Mn porphyrins, commonly regarded as SOD mimics. Anticancer Therapy: Lessons from Brain and Lymphoma Studies. Supplement 2(0) 65. 48. Gridley, D.S., et al., Radiation and a metalloporphyrin radioprotectant in a mouse prostate tumor model. Anticancer Res, 2007. 27(5A): p. 3101-9. 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 70 of 137 49. Rabbani, Z.N., et al., Antiangiogenic action of redox-modulating Mn(III) meso-tetrakis(N-ethylpyridinium-2-yl)porphyrin, MnTE-2-PyP(5+), via suppression of oxidative stress in a mouse model of breast tumor. Free Radic Biol Med, 2009. 47(7): p. 992-1004. 50. Lee, M.Y., Y. Wang, and P.M. Vanhoutte, Senescence of cultured porcine coronary arterial endothelial cells is associated with accelerated oxidative stress and activation of NFkB. J Vasc Res, 2010. 47(4): p. 287-98. 51. Khan, I., I. Batinic-Haberle, and L.T. Benov, Effect of potent redox-modulating manganese porphyrin, MnTM-2-PyP, on the Na(+)/H(+) exchangers NHE-1 and NHE-3 in the diabetic rat. Redox Rep, 2009. 14(6): p. 236-42. 52. Batinic-Haberle, I., J.S. Reboucas, and I. Spasojevic, Superoxide dismutase mimics: chemistry, pharmacology, and therapeutic potential. Antioxid Redox Signal, 2010. 13(6): p. 877-918. 53. Sheng, H., et al., Effects of metalloporphyrin catalytic antioxidants in experimental brain ischemia. Free Radic Biol Med, 2002. 33(7): p. 947-61. 54. Bao, F. and D. Liu, Hydroxyl radicals generated in the rat spi[INVESTIGATOR_591717]: protection by a metalloporphyrin. Neuroscience, 2004. 126(2): p. 285-95. 55. Ling, X. and D. Liu, Temporal and spatial profiles of cell loss after spi[INVESTIGATOR_1828]: Reduction by a metalloporphyrin. J Neurosci Res, 2007. 85(10): p. 2175-85. 56. Liu, D., et al., Peroxynitrite generated at the level produced by [CONTACT_15209][INVESTIGATOR_591718]: reduction by a metalloporphyrin. J Neurotrauma, 2005. 22(10): p. 1123-33. 57. Li, H., et al., Mn(III) meso-tetrakis-(N-ethylpyridinium-2-yl) porphyrin mitigates total body irradiation-induced long-term bone marrow suppression. Free Radic Biol Med, 2011. 51(1): p. 30-7. 58. Weitzel DH, Tovmasyan A, Ashcraft KA, Rajic Z, Weitner T, Liu C, Li W, Buckley AF, Prasad MR, Young KH, Rodriguiz RM, Wetsel WC, Peters KB, Spasojevic I, Herndon JE 2nd, Batinic-Haberle I, Dewhirst MW. Radioprotection of the brain white matter by [CONTACT_591778](III) N-butoxyethylpyridylporphyrin-based superoxide dismutase mimic, MnTnBuOE-2-PyP5+. Mol Cancer Ther. 2015 Jan; 14(1):70-9. PMID: 25319393, PMC4397941. 59. Garofalo, M.C., et al., A pi[INVESTIGATOR_591719] a small molecular weight catalytic metalloporphyrin antioxidant (AEOL [ZIP_CODE]) in mitigating radiation-induced lung damage. Health Phys, 2014. 106(1): p. 73-83. 60. Moeller, B.J., et al., Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity. Cancer Cell, 2005. 8(2): p. 99-110. 61. Semenza, G.L., Oxygen sensing, homeostasis, and disease. N Engl J Med, 2011. 365(6): p. 537-47. 62. Schreck, R., K. Albermann, and P.A. Baeuerle, Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun, 1992. 17(4): p. 221-37. 63. Koga, F., et al., ErbB2 and NFkappaB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer. PLoS One, 2011. 6(11): p. e27616. 64. Weitzel DH, Tovmasyan A, Ashcraft KA, Boico A, Birer SR, Roy Choudhury K, Herndon J 2nd, Rodriguiz RM, Wetsel WC, Peters KB, Spasojevic I, Batinic-Haberle I, Dewhirst MW. Neurobehavioral radiation mitigation to standard brain cancer therapy regimens by [CONTACT_591778](III) n-butoxyethylpyridylporphyrin-based redox modifier. Environ Mol Mutagen 2016 Jun; 57(5):372-81. PMID: 27224425. 65. Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005. 352(10): p. 987-96. 66. Ellingson BM, Wen PY, Cloughesy TF. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics. 2017;14(2):307-20. PMID: 28108885; PMC5398984. 67. Van Belle, S., et al., Comparison of proposed diagnostic criteria with FACT-F and VAS for cancer-related fatigue: proposal for use as a screening tool. Support Care Cancer, 2005. 13(4): p. 246-54. 68. Jacobs, S.R., et al., Evaluation of the functional assessment of cancer therapy cognitive scale with hematopoietic stem cell transplant patients. J Pain Symptom Manage, 2007. 33(1): p. 13-23. 69. Beck, A.T., et al., Comparison of Beck Depression Inventories -IA and -II in psychiatric outpatients. J Pers Assess, 1996. 67(3): p. 588-97. 70. Godin, G. and R.J. Shephard, A simple method to assess exercise behavior in the community. Can J Appl Sport Sci, 1985. 10(3): p. 141-6. 
Protocol #: BMX-HGG-[ADDRESS_780298]: Development of a new memory test with six equivalent forms. Clin Neuropsychol, 1991. 5(2): p. 125–42. 72. Reitan, R. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Mot Skills, 1958. 8: p. 271–6. 73. Ruff, R.M., et al. Benton Controlled Oral Word Association Test: Reliability and updated norms. Arch Clin Neuropsychol, 1996 11: p. 329-38. 74. Cheung, Y.K., Dose Finding by [CONTACT_591779]. 2011. 75. Cheung, Y.K., Coherence principles in dose-finding studies. Biometrika, 2005. 92: p. 863-873. 76. Lee, S.M. and C. Ying Kuen, Model calibration in the continual reassessment method. Clin Trials, 2009. 6(3): p. 227-38. 77. Cheung, M., et al., A method for the consistent creation and quantitative testing of postoperative pelvic adhesions in a porcine model. J Invest Surg, 2009. 22(1): p. 56-62. 78. O'Quigley, J., M. Pepe, and L. Fisher, Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics, 1990. 46(1): p. 33-48. 79. Wen, P.Y., et al., Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol, 2010. 28(11): p. 1963-72. 80. Ratain, M.J. and D.J. Sargent , Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer, 2009. 45(2): p. 275-80. 81. Rubinstein, L.V., et al., Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol, 2005. 23(28): p. 7199-206. 82. Rubinstein, L., et al., Randomized phase II designs. Clin Cancer Res, 2009. 15(6): p. 1883-90.     
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 72 of 137  19 APPENDICES 19.1 Appendix A: RANO (Radiographic Assessment in Neuro-Oncology) Criteria for Newly Diagnosed Patients 	RANO	was	published	in	April	2010	for	the	evaluation	of	HGG	[79]	and	modified	in	2017	[66].	For	newly	diagnosed	HGG	studies,	the	post	radiation	therapy	MRI	scan	is	required	and	is	used	as	the	baseline	scan	for	which	response	will	be	determined.	The	post-operative	MRI	scan	and	pre-entry	MRI	scan	are	also	desired	and	will	vary	based	on	the	requirements	of	clinical	protocols.	In	these	criteria,	particularly	in	regards	to	newly	diagnosed	subjects,	the	areas	considered	in	determining	comprehensive	objective	status	in	RANO	criteria	are	target	lesions	(enhancing	disease),	new	sites	of	measurable	disease,	neurological	examination	status,	and	corticosteroid	usage	and	dose.		Definitions	Measurable	lesions		• Contrast	enhancing		• Two	perpendicular	diameters	≥10mm		• If	slice	+	gap	>	5mm,	minimum	is	2	x	total		• Do	not	include	cavity,	cyst,	or	necrosis	in	the	measurement			Non-measurable	lesions		• Do	not	enhance	(seen	only	on	T2/FLAIR)		• Too	small,	e.g.	12	x	8	mm		• Poorly	defined	margin			
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 73 of 137 Choosing	a	target	lesion	(2)		Target	Lesions:	Take	products	of	diameters	and	add	them	up	→	Sum	of	products	of	diameters	(SPD)			A1	x	B1	+	A2	x	B2	+	…	=	SPD		Complete	Response	(CR):	Requires	all	of	the	following:	§ Disappearance	of	all	enhancing	measurable	and	non-measurable	disease	sustained	for	at	least	[ADDRESS_780299]	scan	exhibiting	disappearance	of	all	enhancing	measurable	and	non-measurable	disease	is	considered	“preliminary	CR”.	If	the	second	scan	exhibits	measurable	enhancing	disease	with	respect	to	the	“preliminary	CR”	scan,	then	the	response	is	not	sustained,	noted	as	“pseudoresponse”,	PsR,	and	is	now	considered	“preliminary	PD”.	If	the	second	scan	continues	to	exhibit	disappearance	of	enhancing	disease	or	emergence	of	non-measurable	disease	(less	than	10mm	bidimensional	product),	it	is	considered	a	durable	CR	and	the	patient	should	continue	on	therapy	until	confirmed	PD	is	observed.	§ Patients	should	be	either	off	of	corticosteroids	or	on	physiologic	replacement	doses	only.	§ Stable	or	improved	neurological	examinations		Partial	Response	(PR):	Requires	all	of	the	following	§ Greater	than	or	equal	to	a	50%	reduction	in	the	size	(products	of	the	largest	perpendicular	diameters)	for	all	enhancing	lesions	compared	with	baseline,	sustained	for	at	least	[ADDRESS_780300]	scan	exhibiting	greater	than	or	equal	to	a	50%	decrease	in	the	sum	of	the	products	of	the	perpendicular	diameters	of	all	measurable	enhancing	lesions	compared	with	the	baseline	is	considered	“preliminary	PR”.	If	the	second	scan	exhibits	PD	with	respect	to	the	“preliminary	PR”	scan,	then	the	response	is	not	sustained,	noted	as	pseudoresponse,	PsR,	and	is	now	considered	“preliminary	PD”	(note	confirmed	PD	requires	at	least	two	sequential	increases	in	tumor	volume.)	If	the	second	scan	exhibits	SD,	PR,	or	CR,	it	is	considered	a	durable	PR	and	the	patient	should	continue	on	therapy	until	confirmed	PD	is	observed.			§ Patients	should	have	either	the	same	corticosteroid	doses	or	on	lower	corticosteroid	dose	compared	with	baseline	scan.		§ Stable	or	improved	neurological	examinations		Stable	Disease	(SD):	Evaluations	that	do	not	meet	criteria	for	CR,	PR	or	PD			Progressive	Disease	(PD):	Defined	as	the	following	§ Greater	than	or	equal	to	a	25%	increase	in	the	product	of	the	largest	perpendicular	diameters	of	any	enhancing	lesion	or	any	new	enhancing	tumor	on	MRI	scans.	The	first	scan	exhibiting	greater	than	or	equal	to	a	25%	increase	in	the	sum	of	the	products	of	perpendicular	diameter	of	the	enhancing	lesions	should	be	compared	to	the	smallest	tumor	measurement	obtained	either	at	baseline	(if	no	decrease)	or	best	response	(on	stable	or	increasing	corticosteroid	dose)	and	is	noted	as	“preliminary	PD”.	If	the	second	scan	at	least	4	weeks	later	exhibits	a	subsequent	greater	than	or	equal	to	25%	increase	in	the	sum	of	products	of	perpendicular	diameters	of	the	enhancing	lesions	relative	to	the	“preliminary	PD”	scan,	it	is	considered	“confirmed	PD”	and	the	patient	should	be	discontinued	from	the	study.	If	the	second	scan	at	least	4	weeks	later	exhibits	SD	or,	PR/CR,	this	scan	showing	“preliminary	PD”	is	noted	as	“pseudoprogression”,	PsP,	and	the	subject	should	remain	on	study	until	a	second	increase	in	tumor	size	relative	to	the	PsP	scan	is	observed.	Of	note,	any	new	measurable	(>	10	mm	X	10	mm)	enhancing	lesion	
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 74 of 137 should	not	be	immediately	considered	PD,	but	instead	should	be	added	to	the	sum	of	the	bidimensional	products	representing	the	entire	enhancing	tumor	burden.			§ In	the	case	where	the	baseline	or	best	response	demonstrates	no	measurable	enhancing	disease	(visible	or	not	visible),	then	any	new	measurable	(>10mm	x	10mm)	enhancing	lesions	are	considered	PD	after	confirmed	by	a	subsequent	scan	≥4	weeks	exhibiting	greater	than	or	equal	to	a	25%	increase	in	sum	of	products	of	perpendicular	diameters	relative	to	the	scan	first	illustrating	new	measurable	disease.	The	first	scan	exhibiting	new	measurable	disease	is	noted	as	“preliminary	PD”.	If	the	second	scan	at	least	4	weeks	later	exhibits	a	subsequent	greater	than	or	equal	to	a	25%	increase	in	sum	of	products	of	perpendicular	of	enhancing	lesions	relative	to	the	“	preliminary	PD”	scan	it	is	considered	“confirmed	PD”	and	the	patient	should	discontinue	therapy.	If	the	second	scan	at	least	4	weeks	later	exhibits	SD,	CR,	PR,	or	becomes	non-measurable,	this	scan	showing	“preliminary	PD”	is	noted	as	“pseudoprogression”,	PsP,	and	the	subject	should	continue	on	study	until	a	second	increase	in	tumor	size	relative	to	the	“preliminary	PD”,	or	PsP,	scan	is	observed.	Note	that	any	new	measurable	(>10mm	x	10mm)	enhancing	lesions	on	the	subsequent	scan	following	the	“preliminary	PD”	scan	should	not	be	immediately	considered	“confirmed	PD”,	but	instead	should	be	added	to	the	sum	of	bidimensional	products	representing	the	entire	enhancing	tumor	burden.		§ Unequivocal	and	significant	worsening	neurological	examination	not	attributable	to	other	causes.		§ Of	note,	if	there	has	been	a	major	reduction	in	steroid	dosage	in	the	interval	and	the	patient	is	felt	to	be	clinically	stable	or	improved,	the	proper	assessment	may	be	“indeterminate”	and	the	therapy	could	be	continued	pending	the	next	evaluation.		§ Failure	to	return	for	evaluation	as	a	result	of	death	or	deteriorating	condition.		Not	Evaluable	(NE):	Progression	has	not	been	documented	and	one	or	more	sites	have	not	been	assessed.		
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 75 of 137 Response	Evaluation:			
	CR=complete	response;	PR=partial	response;	SD=stable	disease;	PD=progressive	disease,	PsP=pseudoprogression,	NE=not	evaluable			Algorithm	for	Newly	Diagnosed	Glioblastoma	(2)		
	MRI	(0)=	pre-entry	MRI,	MRI	(N)=additional	required	MRI	scan,	MRI	(N+1)=follow-up	confirmatory	MRI	scan.	Please	note	that	while	this	figure	references	volumetric	analysis,	our	standard	operating	procedure	is	to	use	bi-dimensional	measures.					

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 76 of 137 	19.2 Appendix B: Pharmacokinetic Analysis 19.2.1  Phase 1 Pharmacokinetic Analysis The major goal of the pharmacokinetic studies conducted in conjunction with this protocol will be to determine pharmacokinetics of BMX-001 in combination with RT and TMZ. These samples will be collected from patients during chemoradiation phase only.  Pharmacokinetic Assessment of BMX-001:. A series of blood samples will be taken for the measurement of the compound in order to define pharmacokinetics in these patients. Patients should have their dose administered on the same time of day. Instructions for the handling and shippi[INVESTIGATOR_591720]-001 are provided below. Blood sample volumes and schedule of samples are specified below.  Pharmacokinetic Blood Sample Collection and Handling: Blood samples (4 ml) will be collected into pre-cooled (ice bath) heparinized tubes and gently inverted 8-10 times and immediately placed in the ice bath. Within 30 minutes, plasma will be prepared by [CONTACT_7891] (2000 x g, 40C, 10 min). Following centrifugation, 1 mL plasma will be transferred by [CONTACT_591780][INVESTIGATOR_350863] a 2-mL polypropylene cryogenic vial containing 20 µL of 50% citric acid, inverted 8-10 times, and stored frozen at -800C until shipment and analysis.  Blood Sampling Time Schedule for BMX-001: Drug pharmacokinetics will be obtained on loading dose day, Day 8 or the next date on which drug is administered, and Day 36 or the next date on which drug is administered during the chemoradiation phase. Measures will be obtained at the following time-points: Pre Dose, 0.[ADDRESS_780301] maintenance dose of the sixth week following initiation of radiation therapy. PK Labelling: PK samples will labelled such that they are blinded to [CONTACT_591787]’s labs. The cyro-vials provided to his lab will labelled with random numbers generated by [CONTACT_591781] a master file maintained by [CONTACT_3476]. Samples will not be identified by [CONTACT_4676], timepoint, dose level or cohort prior to being analysed by [INVESTIGATOR_124]. Spasojevic. Data generated by [CONTACT_591782]. Labelling and blinding procedures will be specified in the Blood Collection and Plasma Separation Storage SOP.  Analytical Method: Concentrations of BMX-001 will be determined using a high-pressure liquid chromatography – tandem-mass spectrometry (LC/MS/MS) by [CONTACT_591783], LLC.   Samples will be taken/shipped to [CONTACT_591787] at the following address: Ivan Spasojevic, PhD Pharmacology Lab Duke Hospi[INVESTIGATOR_591721], Room [ADDRESS_780302] Durham, NC [ZIP_CODE] Tel: [PHONE_12272] Cell: [PHONE_12273] Fax: [PHONE_12274]  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 77 of 137 Pharmacokinetic Sample Collection for BMX-001 in Combination with Current Chemoradiation Phase 1 Study Day Timing Range of time to be collected within Loading Dose Day Pre-dose N/A [ADDRESS_780303]-dose +/- [ADDRESS_780304]-dose +/- [ADDRESS_780305]-dose +/- [ADDRESS_780306]-dose +/- [ADDRESS_780307]-dose +/- 10 minutes Day 8 or the next day when drug is administered Pre-dose N/A [ADDRESS_780308]-dose +/- [ADDRESS_780309]-dose +/- [ADDRESS_780310]-dose +/- [ADDRESS_780311]-dose +/- [ADDRESS_780312]-dose +/- 10 minutes Day 36 or the next day when drug is administered Pre-dose N/A [ADDRESS_780313]-dose +/- [ADDRESS_780314]-dose +/- [ADDRESS_780315]-dose +/- [ADDRESS_780316]-dose +/- [ADDRESS_780317]-dose +/- 10 minutes  19.2.2 Phase 2 Pharmacokinetic Analysis In order to provide a wider population sample for pharmacokinetics, we will obtain sparse sampling from 6 patients in the Phase 2 Arm A portion of the study.   The major goal of the pharmacokinetic studies conducted in conjunction with this protocol will be to determine pharmacokinetics of BMX-001 in combination with RT and TMZ. These samples will be collected from patients during chemoradiation phase only.  Pharmacokinetic Assessment of BMX-001: A series of blood samples will be taken for the measurement of the compound in order to define pharmacokinetics in these patients. Patients should have their dose administered on the same time of day. Instructions for the handling and shippi[INVESTIGATOR_591720]-001 are provided below. Blood sample volumes and schedule of samples are specified below.  Pharmacokinetic Blood Sample Collection and Handling: Blood samples (4 ml) will be collected into pre-cooled (ice bath) heparinized tubes and gently inverted 8-10 times and immediately placed in the ice bath. Within 30 minutes, plasma will be prepared by [CONTACT_7891] (2000 x g, 40C, 10 min). Following centrifugation, 1 mL plasma will be transferred by [CONTACT_591780][INVESTIGATOR_591722] 2-mL polypropylene cryogenic vial aliquots containing 20 µL of 50% citric acid, inverted 8-10 times, and stored frozen at -800C until shipment and analysis. One aliquot is acceptable if samples are not being shipped. Blood Sampling Time Schedule for BMX-001: Drug pharmacokinetics will be obtained on Day 8 or the next day when drug is administered and Day 36 or the next day when drug is administered during the chemoradiation phase. Measures will be obtained at the following time-points: Pre Dose, 0.5 hour, 1 hour, 2 hours, 6 hours and 24 hours. 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 78 of 137 Analytical Method: Concentrations of BMX-001 will be determined using a high-pressure liquid chromatography – tandem-mass spectrometry (LC/MS/MS) by [CONTACT_591783], LLC.   Samples will be taken/shipped to [CONTACT_591787] at the following address: Ivan Spasojevic, PhD Pharmacology Lab Duke Hospi[INVESTIGATOR_591721], Room [ADDRESS_780318] Durham, NC [ZIP_CODE] Tel: [PHONE_12272] Cell: [PHONE_12273] Fax: [PHONE_12274]  Pharmacokinetic Sample Collection for BMX-001 in Combination with Current Chemoradiation Phase 2 Study Day Timing Range of time to be collected within Day 8 or the next day when drug is administered Pre-dose N/A [ADDRESS_780319]-dose +/- [ADDRESS_780320]-dose +/- [ADDRESS_780321]-dose +/- [ADDRESS_780322]-dose +/- [ADDRESS_780323]-dose +/- 10 minutes Day 36 or the next day when drug is administered Pre-dose N/A [ADDRESS_780324]-dose +/- [ADDRESS_780325]-dose +/- [ADDRESS_780326]-dose +/- [ADDRESS_780327]-dose +/- [ADDRESS_780328]-dose +/- 10 minutes  19.3 APPENDIX C: Statistical Tables 19.3.[ADDRESS_780329] STAGE WITH COHORTS OF 3 Initial Guess of Toxicity Probability=0.101 / 0.143 / 0.193 / 0.25 (delta=0.03; logistic)   True Probability of DLT=0.05 / 0.055 / 0.06 / 0.065 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0020 0.0060 0.0250 0.9670 21 0.0020 0.0060 0.0145 0.9775 24 0.0000 0.0035 0.0095 0.9870  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 79 of 137 True Probability of DLT=0.05 / 0.07 / 0.11 / 0.2 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0045 0.0220 0.0815 0.8920 21 0.0030 0.0200 0.0830 0.8940 24 0.0010 0.0140 0.0790 0.9060  True Probability of DLT=0.05 / 0.05 / 0.15 / 0.25 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0050 0.0290 0.1270 0.8390 21 0.0050 0.0305 0.1420 0.8225 24 0.0010 0.0210 0.1770 0.8010  True Probability of DLT=0.1 / 0.25 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.2395 0.3665 0.2455 0.1485 21 0.2315 0.3970 0.2645 0.1070 24 0.2390 0.4285 0.2600 0.0725  True Probability of DLT=0.2 / 0.2 / 0.3 / 0.4 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.3230 0.1915 0.2470 0.2385 21 0.3010 0.2430 0.2285 0.2275 24 0.2920 0.2590 0.2715 0.1775  True Probability of DLT=0.2 / 0.3 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.4900 0.2455 0.1705 0.0940 21 0.4775 0.2945 0.1605 0.0675 24 0.5050 0.2935 0.1595 0.0420  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 80 of 137 Initial Guess of Toxicity Probability=0.044 / 0.089 / 0.158 / 0.25 (delta=0.05; logistic)   True Probability of DLT=0.05 / 0.055 / 0.06 / 0.065 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0030 0.0205 0.0465 0.9300 21 0.0015 0.0125 0.0475 0.9385 24 0.0015 0.0095 0.0280 0.9610  True Probability of DLT=0.05 / 0.07 / 0.11 / 0.2 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0045 0.0305 0.1335 0.8315 21 0.0020 0.0255 0.1390 0.8335 24 0.0015 0.0180 0.1315 0.8490  True Probability of DLT=0.05 / 0.05 / 0.15 / 0.25 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0030 0.0375 0.2020 0.7575 21 0.0015 0.0335 0.2160 0.7490 24 0.0015 0.0225 0.2215 0.7545  True Probability of DLT=0.1 / 0.25 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.2040 0.4325 0.2820 0.0815 21 0.1855 0.4765 0.2810 0.0570 24 0.1840 0.5280 0.2490 0.0390  True Probability of DLT=0.2 / 0.2 / 0.3 / 0.4 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.3200 0.2405 0.2740 0.1655 21 0.3050 0.2650 0.2900 0.1400 24 0.2935 0.2770 0.3040 0.1255  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 81 of 137 True Probability of DLT=0.2 / 0.3 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.4685 0.3100 0.1735 0.0480 21 0.4635 0.3370 0.1680 0.0315 24 0.4555 0.3760 0.1410 0.0275  Initial Guess of Toxicity Probability=0.016 / 0.051 / 0.124 / 0.250 (delta=0.07; logistic)   True Probability of DLT=0.05 / 0.055 / 0.06 / 0.065 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0030 0.0410 0.0905 0.8655 21 0.0020 0.0250 0.1070 0.8660 24 0.0020 0.0160 0.0730 0.9090  True Probability of DLT=0.05 / 0.07 / 0.11 / 0.2 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0030 0.0690 0.2005 0.7275 21 0.0035 0.0470 0.2170 0.7325 24 0.0025 0.0310 0.2010 0.7655  True Probability of DLT=0.05 / 0.05 / 0.15 / 0.25 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0030 0.0530 0.2710 0.6730 21 0.0015 0.0330 0.3205 0.6450 24 0.0020 0.0245 0.2920 0.6815  True Probability of DLT=0.1 / 0.25 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.1765 0.5295 0.2385 0.0555 21 0.1605 0.5580 0.2480 0.0335 24 0.1525 0.5875 0.2400 0.0200  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 82 of 137 True Probability of DLT=0.2 / 0.2 / 0.3 / 0.4 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.3240 0.3060 0.2420 0.1280 21 0.3320 0.3135 0.2730 0.0815 24 0.2905 0.3320 0.2795 0.0980  True Probability of DLT=0.2 / 0.3 / 0.4 / 0.[ADDRESS_780330] STAGE WITH COHORTS OF 3  Initial Guess of Toxicity Probability=0.097 / 0.141 / 0.192 / 0.25 (delta=0.03; empi[INVESTIGATOR_29121])   True Probability of DLT=0.05 / 0.055 / 0.06 / 0.065 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0020 0.0060 0.0250 0.9670 21 0.0020 0.0060 0.0170 0.9750 24 0.0000 0.0035 0.0100 0.9865  True Probability of DLT=0.05 / 0.07 / 0.11 / 0.2 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0045 0.0185 0.0835 0.8935 21 0.0035 0.0200 0.0820 0.8945 24 0.0010 0.0130 0.0705 0.9155  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 83 of 137 True Probability of DLT=0.05 / 0.05 / 0.15 / 0.25 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0050 0.0265 0.1280 0.8405 21 0.0050 0.0305 0.1395 0.8250 24 0.0015 0.0210 0.1540 0.8235  True Probability of DLT=0.1 / 0.25 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.2465 0.3540 0.2525 0.1470 21 0.2285 0.4025 0.2600 0.1090 24 0.2340 0.4285 0.2570 0.0805  True Probability of DLT=0.2 / 0.2 / 0.3 / 0.4 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.3260 0.1860 0.2480 0.2400 21 0.3000 0.2420 0.2355 0.2225 24 0.2920 0.2555 0.2585 0.1940  True Probability of DLT=0.2 / 0.3 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.4935 0.2360 0.1780 0.0925 21 0.4760 0.2960 0.1605 0.0675 24 0.5025 0.2955 0.1545 0.0475  Initial Guess of Toxicity Probability=0.036 / 0.084 / 0.157 / 0.25 (delta=0.05; empi[INVESTIGATOR_29121])   True Probability of DLT=0.05 / 0.055 / 0.06 / 0.065 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0050 0.0160 0.0430 0.9360 21 0.0020 0.0155 0.0430 0.9395 24 0.0010 0.0120 0.0330 0.9540  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 84 of 137 True Probability of DLT=0.05 / 0.07 / 0.11 / 0.2 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0055 0.0260 0.1335 0.8350 21 0.0020 0.0255 0.1250 0.8475 24 0.0015 0.0190 0.1205 0.8590  True Probability of DLT=0.05 / 0.05 / 0.15 / 0.25 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0045 0.0305 0.2050 0.7600 21 0.0020 0.0325 0.2090 0.7565 24 0.0010 0.0185 0.2275 0.7530  True Probability of DLT=0.1 / 0.25 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.1755 0.4645 0.2600 0.1000 21 0.1835 0.4690 0.2955 0.0520 24 0.1430 0.5430 0.2700 0.0440  True Probability of DLT=0.2 / 0.2 / 0.3 / 0.4 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.3030 0.2635 0.2635 0.1700 21 0.2920 0.2850 0.2750 0.1480 24 0.2805 0.2875 0.3020 0.1300  True Probability of DLT=0.2 / 0.3 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.4520 0.3415 0.1520 0.0545 21 0.4705 0.3325 0.1680 0.0290 24 0.4415 0.3755 0.1560 0.0270  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 85 of 137 Initial Guess of Toxicity Probability=0.009 / 0.043 / 0.124 / 0.25 (delta=0.07; empi[INVESTIGATOR_29121])   True Probability of DLT=0.05 / 0.055 / 0.06 / 0.065 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0040 0.0400 0.0880 0.8680 21 0.0015 0.0285 0.1100 0.8600 24 0.0015 0.0255 0.0820 0.8910  True Probability of DLT=0.05 / 0.07 / 0.11 / 0.2 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0045 0.0605 0.1770 0.7580 21 0.0020 0.0450 0.2385 0.7145 24 0.0025 0.0410 0.2030 0.7535  True Probability of DLT=0.05 / 0.05 / 0.15 / 0.25 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.0045 0.0500 0.2560 0.6895 21 0.0015 0.0445 0.3085 0.6455 24 0.0015 0.0330 0.3060 0.6595  True Probability of DLT=0.1 / 0.25 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.1845 0.5150 0.2400 0.0605 21 0.1655 0.5685 0.2305 0.0355 24 0.1460 0.6090 0.2215 0.0235  True Probability of DLT=0.2 / 0.2 / 0.3 / 0.4 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 18 0.3185 0.3260 0.2375 0.1180 21 0.3185 0.3200 0.2720 0.0895 24 0.3010 0.3435 0.2830 0.0725  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 86 of 137 True Probability of DLT=0.2 / 0.3 / 0.4 / 0.[ADDRESS_780331] STAGE WITH COHORTS OF 3  Initial Guess of Toxicity Probability=0.101 / 0.143 / 0.193 / 0.25 (delta=0.03; logistic)   True Probability of DLT=0.05 / 0.055 / 0.06 / 0.065 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.008 0.020 0.032 0.940 18 0.004 0.006 0.030 0.960 20 0.000 0.010 0.016 0.974  True Probability of DLT=0.05 / 0.07 / 0.11 / 0.2 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.016 0.032 0.106 0.846 18 0.004 0.024 0.116 0.856 20 0.002 0.036 0.118 0.844  True Probability of DLT=0.05 / 0.05 / 0.15 / 0.25 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.014 0.062 0.128 0.796 18 0.004 0.036 0.162 0.798 20 0.004 0.042 0.160 0.794  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 87 of 137 True Probability of DLT=0.1 / 0.25 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.266 0.304 0.260 0.170 18 0.250 0.378 0.254 0.118 20 0.262 0.374 0.262 0.102  True Probability of DLT=0.2 / 0.2 / 0.3 / 0.4 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.372 0.170 0.198 0.260 18 0.328 0.190 0.260 0.222 20 0.348 0.204 0.258 0.190  True Probability of DLT=0.2 / 0.3 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.502 0.228 0.162 0.108 18 0.500 0.252 0.180 0.068 20 0.508 0.262 0.176 0.054  Initial Guess of Toxicity Probability=0.044 / 0.089 / 0.158 / 0.25 (delta=0.05; logistic)   True Probability of DLT=0.05 / 0.055 / 0.06 / 0.065 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.006 0.024 0.072 0.898 18 0.006 0.022 0.060 0.912 20 0.008 0.014 0.050 0.928  True Probability of DLT=0.05 / 0.07 / 0.11 / 0.2 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.008 0.050 0.154 0.788 18 0.008 0.036 0.162 0.794 20 0.008 0.034 0.134 0.824  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 88 of 137 True Probability of DLT=0.05 / 0.05 / 0.15 / 0.25 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.006 0.062 0.222 0.710 18 0.008 0.042 0.228 0.722 20 0.008 0.038 0.204 0.750  True Probability of DLT=0.1 / 0.25 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.202 0.450 0.256 0.092 18 0.194 0.472 0.254 0.080 20 0.180 0.504 0.252 0.064  True Probability of DLT=0.2 / 0.2 / 0.3 / 0.4 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.290 0.308 0.216 0.186 18 0.310 0.282 0.252 0.156 20 0.284 0.302 0.268 0.146  True Probability of DLT=0.2 / 0.3 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.454 0.326 0.156 0.064 18 0.464 0.322 0.164 0.050 20 0.446 0.362 0.154 0.038  Initial Guess of Toxicity Probability=0.016 / 0.051 / 0.124 / 0.250 (delta=0.07; logistic)   True Probability of DLT=0.05 / 0.055 / 0.06 / 0.065 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.024 0.034 0.078 0.864 18 0.010 0.038 0.088 0.864 20 0.012 0.026 0.090 0.872  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 89 of 137 True Probability of DLT=0.05 / 0.07 / 0.11 / 0.2 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.028 0.064 0.188 0.720 18 0.012 0.056 0.202 0.730 20 0.014 0.036 0.226 0.724  True Probability of DLT=0.1 / 0.25 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.230 0.480 0.226 0.064 18 0.190 0.510 0.246 0.054 20 0.224 0.486 0.236 0.054  True Probability of DLT=0.2 / 0.2 / 0.3 / 0.4 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.392 0.262 0.192 0.154 18 0.348 0.302 0.216 0.134 20 0.374 0.234 0.272 0.120  True Probability of DLT=0.2 / 0.3 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.514 0.300 0.160 0.026 18 0.488 0.330 0.142 0.040 20 0.478 0.346 0.144 0.032  
Protocol #: BMX-HGG-[ADDRESS_780332] STAGE WITH COHORTS OF 3  Initial Guess of Toxicity Probability=0.097 / 0.141 / 0.192 / 0.25 (delta=0.03; empi[INVESTIGATOR_29121])   True Probability of DLT=0.05 / 0.055 / 0.06 / 0.065 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.006 0.018 0.022 0.954 18 0.010 0.012 0.022 0.956 20 0.004 0.012 0.024 0.960  True Probability of DLT=0.05 / 0.07 / 0.11 / 0.2 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.012 0.038 0.078 0.872 18 0.010 0.030 0.086 0.874 20 0.006 0.028 0.108 0.858  True Probability of DLT=0.05 / 0.05 / 0.15 / 0.25 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.010 0.040 0.124 0.826 18 0.010 0.040 0.116 0.834 20 0.006 0.046 0.184 0.764  True Probability of DLT=0.1 / 0.25 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.250 0.336 0.276 0.138 18 0.280 0.350 0.240 0.130 20 0.244 0.448 0.222 0.086  True Probability of DLT=0.2 / 0.2 / 0.3 / 0.4 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.322 0.222 0.188 0.268 18 0.312 0.216 0.222 0.250 20 0.342 0.218 0.264 0.176 
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 91 of 137  True Probability of DLT=0.2 / 0.3 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.498 0.244 0.170 0.088 18 0.480 0.268 0.164 0.088 20 0.498 0.322 0.122 0.058  Initial Guess of Toxicity Probability=0.036 / 0.084 / 0.157 / 0.25 (delta=0.05; empi[INVESTIGATOR_29121])   True Probability of DLT=0.05 / 0.055 / 0.06 / 0.065 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.008 0.022 0.062 0.908 18 0.002 0.016 0.048 0.934 20 0.000 0.024 0.032 0.944  True Probability of DLT=0.05 / 0.07 / 0.11 / 0.2 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.010 0.048 0.156 0.786 18 0.002 0.034 0.140 0.824 20 0.000 0.036 0.146 0.818  True Probability of DLT=0.05 / 0.05 / 0.15 / 0.25 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.008 0.046 0.192 0.754 18 0.002 0.034 0.230 0.734 20 0.000 0.036 0.188 0.776  True Probability of DLT=0.1 / 0.25 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.188 0.472 0.246 0.094 18 0.220 0.456 0.254 0.070 20 0.170 0.530 0.252 0.048  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 92 of 137 True Probability of DLT=0.2 / 0.2 / 0.3 / 0.4 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.304 0.282 0.240 0.174 18 0.308 0.278 0.250 0.164 20 0.294 0.296 0.264 0.146  True Probability of DLT=0.2 / 0.3 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.456 0.342 0.158 0.044 18 0.488 0.306 0.178 0.028 20 0.436 0.394 0.144 0.026  Initial Guess of Toxicity Probability=0.009 / 0.043 / 0.124 / 0.25 (delta=0.07; empi[INVESTIGATOR_29121])   True Probability of DLT=0.05 / 0.055 / 0.06 / 0.065 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.006 0.036 0.158 0.800 18 0.006 0.042 0.084 0.868 20 0.006 0.018 0.084 0.892  True Probability of DLT=0.05 / 0.07 / 0.11 / 0.2 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.006 0.076 0.262 0.656 18 0.010 0.064 0.234 0.692 20 0.006 0.046 0.218 0.730  True Probability of DLT=0.05 / 0.05 / 0.15 / 0.25 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.006 0.054 0.326 0.614 18 0.006 0.054 0.316 0.624 20 0.006 0.034 0.302 0.658  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 93 of 137 True Probability of DLT=0.1 / 0.25 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.218 0.488 0.224 0.070 18 0.198 0.522 0.224 0.056 20 0.180 0.544 0.238 0.038  True Probability of DLT=0.2 / 0.2 / 0.3 / 0.4 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.366 0.278 0.240 0.116 18 0.364 0.286 0.244 0.106 20 0.344 0.306 0.254 0.096  True Probability of DLT=0.2 / 0.3 / 0.4 / 0.5 n Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 16 0.510 0.318 0.134 0.038 18 0.508 0.334 0.126 0.032 20 0.472 0.374 0.138 0.016   19.4 Appendix D Cytochrome P450 Drug Interaction Table  Please see the following website for known cytochrome P450 inducers and strong inhibitors. The website is updated frequently as new information becomes available (Flockhart, 2007)  http://medicine.iupui.edu/clinpharm/ddis/main-table/  Dexamethasone is listed on this table, but is allowed in this protocol.               
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 94 of 137 19.5 Appendix E Copy of BAC App screenshots 
 
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 95 of 137  
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 96 of 137   
      

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 97 of 137  
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 98 of 137  
  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 99 of 137  
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 100 of 137  
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 101 of 137  
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 102 of 137  
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 103 of 137  19.6 Appendix F:  Beck Depression Inventory- II (BDI-II) 
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 104 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 105 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 106 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 107 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 108 of 137     

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 109 of 137  19.7 Appendix G:  FACIT-Fatigue 
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 110 of 137 19.8 Appendix H:  Fact-BR 
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 111 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 112 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 113 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 114 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 115 of 137 19.9  Appendix I:  FACT-Cog 
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 116 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 117 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 118 of 137 19.10 Appendix J:  Godin Leisure-Time Exercise Questionnaire 
  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 119 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 120 of 137 19.11 Appendix K:  Trails Making Test (TMT) Parts A & B 
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 121 of 137  
-Total time to complete in seconds: ____________ - Number of errors: ____________  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 122 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 123 of 137  
-Total time to complete in seconds: ____________ - Number of errors: ____________  
Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 124 of 137   

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 125 of 137 19.12 Appendix L:  HVLT-R Forms 1, 2 and 3  
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 126 of 137      

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 127 of 137     

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 128 of 137  
 

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 129 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 130 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 131 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 132 of 137   

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 133 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 134 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 135 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 136 of 137  

Protocol #: BMX-HGG-001 Version 9.0, 25 May 2021 
Page 137 of 137 19.1 Appendix M:  COWA 
   
